Protocol Version:  05/16/2022 – Amendment 7  Page 1 of 83  
 
A phase I/II study to evaluate the tolerability and efficacy of BMS -813160 (CCR2/5 inhibitor) with  
nivolumab  and gemcitabine and nab- paclitaxel  in borderline resectable and locally advanced 
pancreatic ductal adenocarcinoma (PDAC)  
 
Washington University School of Medicine  / Division of Oncology  
[ADDRESS_1180967]. Louis, MO  [ZIP_CODE]  
 
Protocol  #: 201806007  
Version Date: 05/16 /2022  
 
Coordinating Center:   Washington University School of Medicine  
Principal Investigator:   [INVESTIGATOR_195568] -Huat Lim , M.D., Ph.D. 
Phone: (314) 362- 6157 
E-mail: kian -[EMAIL_3875]   
 
Sub- Investigators    Institution    Modality  
Benjamin Tan, M.D.    Washington University   Medical Oncology  
Katrina Pederse n, M.D.    Washington University   Medical Oncology  
Rama Suresh, M.D.    Washington University   Medical Oncology  
Haeseong Park, M.D.    Washington University   Medical Oncology  
Nikolaos Trikalinos, M.D.   Washington University   Medical Oncology  
William Hawkins, M.D.    Washington University   Surgery  
Ryan Fields, M.D.    Washington University   Surgery  
Maria Majella Doyle, M.D.   Washington University   Surgery  
Chet Hammill, M. D.   Washington University   Surgery  
Vladimir Kushnir, M.D.    Washington University   Gastroenterology  
Marianne Ruzinova, M.D., Ph.D. Washington University   Pathology  
David DeNardo, Ph.D.    Washington University   Tumor Immunology 
Esther L u, Ph.D.    Washingt on University  Biostatistics  
 
Study Drug(s):    BMS -813160 
Nivolumab  Gemcitabine (Gemzar)  
Nab-paclitaxel (Abraxane)  
IND #:  139562  
ClinicalTrials.gov  #: [STUDY_ID_REMOVED]  
 
CONFIDENTIAL  
The information contained in this document is regarded as confidential and, except to the extent necessary to 
obtain informed consent, may not be disclosed to another party unless law or regulations require such 
disclosure.  Persons to whom the information is disclosed must be informed that the information is 
confidential and may not be further disclosed by [CONTACT_849384]:  05/16/2022 – Amendment 7  Page 2 of 83 A phase I/II study to evaluate the tolerability and efficacy of BMS -813160 (CCR2/5 
inhibitor) with nivolumab and gemcitabine and nab- paclitaxel in borderline resectable and 
locally advanced pancreatic ductal adenocarcinoma (PDAC)  
 
Protocol Revision History  
 
Initial Approval Version        05/29/ 2018 
Amendment #1 Version        08/27/2018 
Amendment # 2 Version        04/15/2019 
Amendment # 3 Version        06/05/2019 
Amendment # 4 Version        09/18/2019 
Amendment #5 Version        03/20/2020 
Amendment #6 Version        07/28/2021 
Amendment #7 Version        05/23/2022 
 
  
Protocol Version:  05/16/2022 – Amendment 7  Page 3 of 83 A phase I/II study to evaluate the tolerability and efficacy of BMS -813160 (CCR2/5 
inhibitor) with nivolumab and gemcitabine and nab- paclitaxel in borderline resectable and 
locally advanced pancreatic ductal adenocarcinoma (PDAC)  
 
Principal Investigator [INVESTIGATOR_205050] 
(printed):        
Name [CONTACT_50663]:        
  
 PI [INVESTIGATOR_725379], I agree to personally supervise the conduct of this study 
and to ensure its conduct in compliance with the protocol, informed 
consent, IRB/HRPO procedures, the Declaration of Helsinki, ICH Good 
Clinical Practices guidelines, and the applicable parts of the United 
States Code of Federal Regulations or l ocal regulations governing the 
conduct of clinical studies.  
 
   
Protocol Version:  05/16/2022 – Amendment 7  Page 4 of 83 A phase I/II study to evaluate the tolerability and efficacy of BMS -813160 (CCR2/5 
inhibitor) with nivolumab and gemcitabine and nab- paclitaxel in borderline resectable and 
locally advanced pancreatic ductal adenocarcinoma (PDAC)  
 
SCHEMA  
 
  

Protocol Version:  05/16/2022 – Amendment 7  Page 5 of 83  
Part A: Safety Lead -In (Each cycle = 28 days)  
Arm (by 
[CONTACT_17628])  BMS -813160  (D1-28) Nivolumab 
(D1)  Chemotherapy  (D1, 8, 15)  
Dose Level  Dose  Dose Level  Gemcitabine  Nab-paclitaxel  
Experimental 
(n=9- 18) 0 (starting)  300 mg BID  480 mg  0 (starting)  1000 mg/m2 125 mg/m2 
-1 150 mg  BID  480 mg  -1 800 mg/m2 100 mg/m2 
-2 150 mg  QD  480 mg  -2 600 mg/m2 75 mg/m2 
Control (n=8)  N/A N/A N/A 0 (starting)  1000 mg/m2 125 mg/m2 
N/A N/A N/A -1 800 mg/m2 100 mg/m2 
N/A N/A N/A -2 600 mg/m2 75 mg/m2 
Part B: Dose Expansion (Each cycle = 28 days)  
Dose expansion 
(N=30 *)  Per Part A  [ADDRESS_1180968] be made based on toxicities attributed to BMS -813160 or  chemotherapy, or both.  
G-CSF not allowed for C ycles 1-2 
* Total of 30 patients includes patients started on and stayed on MTD on experimental arm in Part A  
 
 
 
 
  
Protocol Version:  05/16/2022 – Amendment 7  Page 6 of 83 Glossary of Abbreviations  
 
AE Adverse event  
ALT (SGPT)  Alanine transaminase (serum glutamate pyruvic transaminase)  
ANC  Absolute neutrophil count  
AST (SGOT)  Aspartate transaminase (serum glutamic oxaloacetic transaminase)  
B-HCG  Beta human chorionic gonadotropin  
CAF  Cancer -associated fibroblast  
CBC  Complete blood count  
CTL  Cytotoxic T lymphocyte  
CNS  Central nervous system  
CR Complete re sponse  
CRC  Colorectal cancer  
CRF  Case report form  
CT Computed tomography 
CTCAE  Common Terminology Criteria for Adverse Events  
CTEP  Cancer Therapy Evaluation Program  
DLT  Dose limiting toxicity  
DSMC  Data Safety Monitoring  Committee  
ECOG  Eastern Cooperative Oncology Group 
FDA  Food and Drug Administration 
HCC  Hepatocellular carcinoma  
HIV Human Immunodeficiency Virus  
HRPO  Human Research Protection Office (IRB)  
IM Inflammatory monocyte  
IND Investigational New Drug  
IRB Institutional Review Board  
IULN  Institutional upper limit of normal  
MRI  Magnetic resonance imaging  
MTD  Maximum tolerated dose 
NCI National Cancer Institute  
NIH National Institutes of Health  
NSAID  Non-steroidal anti -inflammatory drug  
OHRP  Office of Human Research Protections  
ORR  Overall response rate  
OS Overall survival  
PB Peripheral blood  
PD Pharmacodynamic  
PD Progressive disease  
PDAC  Pancreatic ductal adenocarcinoma  
PFS Progression -free survival  
PI [INVESTIGATOR_321772]:  05/16/2022 – Amendment [ADDRESS_1180969]  Response Evaluation Criteria in Solid Tumors (Committee)  
SAE  Serious adverse event  
SCC  Siteman Cancer Center  
SD Stable disease  
TAM  Tumor -associated macrophage 
TME  Tumor microenvironment  
UPN Unique patient number  
WUSM  Washington University School of Medicine  
  
Protocol Version:  05/16/2022 – Amendment 7  Page 8 of 83 Table of Contents  
SCHEMA ........................................................................................................................................ 4 
1 BACKGROUND AND RATIONALE  .............................................................................. 10 
1.1 Pancreatic Ductal Adenocarcinoma (PDAC)  ................................................................. 10 
1.2 BMS -813160  .................................................................................................................. 10 
1.3 Nivolumab (Opdivo)  ...................................................................................................... 12 
1.4 Summar y of common or significant side effects for each agent  .................................... 13 
1.5 Study Rationale  .............................................................................................................. 13 
1.6 Correlative Studies Background ..................................................................................... 14 
2 OBJECTIVES  .................................................................................................................... 16 
2.1 Primary Objectives  ......................................................................................................... 16 
2.2 Secondary Objectives (Part B)  ....................................................................................... 16 
2.3 Exploratory Objectives (Parts A and B)  ......................................................................... 16 
3 PATIENT SELECTION  .................................................................................................... 17 
3.1 Inclusion Criteria  ............................................................................................................ 17 
3.2 Exclusion Criteria  ........................................................................................................... 18 
3.3 Inclus ion of Women and Minorities ............................................................................... 20 
4 REGISTRATION PROCEDURES  ................................................................................... 20 
4.1 Confirmation of Patient Eligibility  ................................................................................. 20 
4.2 Patient Registration in the Siteman Cancer Center OnCore Database  ........................... 21 
4.3 Assignment of UPN  ....................................................................................................... 21 
5 TREATMENT PLAN  ........................................................................................................ 21 
5.1 Agent Admini stration  ..................................................................................................... 22 
5.2 Dose De -Escalation Schema – Part A  ............................................................................ 23 
5.3 Definition of MTD, DLT, and Dose Escalation Criteria – Part A  ................................. 23 
5.4 Toxicity, Response, and DLT Evaluations  .................................................................... 25 
5.5 Part B – Dose Expansion  ................................................................................................ 26 
5.6 General Concomitant Medication and Supportive Care Guidelines  .............................. 26 
5.7 Women of Childbearing Potential (WOCBP)  ................................................................ 26 
5.8 Duration of Therapy  ....................................................................................................... 27 
5.9 Duration of Follow -up .................................................................................................... 28 
6 DOSE DELAYS/DOSE MODIFICATIONS  .................................................................... 28 
6.1 Dose Modifications for BMS -813160  ............................................................................ 29 
6.2 Dose Modifications for Nivolumab................................................................................ 30 
6.3 Dose Modifications for Gemcitabine and Nab- Paclitaxel  .............................................. 31 
6.4 Treatment Beyond Progression ...................................................................................... 33 
7 REGULATORY AND REPORTING REQUIREMENTS  ............................................... 34 
7.1 Sponsor -Investigator Reporting Requirements  .............................................................. 34 
7.2 Reporting Requirements for Secondary Sites  ................................................................ 38 
8 PHARMACEUTICAL INFORMATION  .......................................................................... 39 
8.1 BMS -813160  .................................................................................................................. 39 
8.2 Nivolumab (Opdivo)  ...................................................................................................... 40 
8.3 Gemcitabine (Gemzar)  ................................................................................................... 42 
8.4 Nab-Paclitaxel (Abraxane)  ............................................................................................. 44 
9 CORRELATIVE STUDIES  .............................................................................................. 45 
9.1 Tumor Biopsy  ................................................................................................................. 45 
Protocol Version:  05/16/2022 – Amendment [ADDRESS_1180970] – Solid Tumors ................................................................................... 50 
12.2 Disease Parameters  ......................................................................................................... 51 
12.3 Methods for Evaluation of Measurable Disease  ............................................................ 52 
12.4 Response Criteria  ........................................................................................................... 54 
13 DATA AND SAFETY MONITORING  ............................................................................ 56 
14 AUDITING  ........................................................................................................................ 58 
15 STATISTICAL CONSIDERATIONS ............................................................................... 58 
15.1 Part A .............................................................................................................................. 58 
15.2 Part B  .............................................................................................................................. 59 
15.3 Statistical analysis  .......................................................................................................... 59 
16 MULTICENTER REGULATORY REQUIREMENTS  ................................................... 60 
17 REFERENCES  .................................................................................................................. 62 
APPENDIX A: ECOG Performance Status Scale  ........................................................................ 65 
APPENDIX B: PATIENT’S MEDICATION DIARY ................................................................. 66 
APPENDIX C: CYP3A4 and P -GP Guidance .............................................................................. 67 
APPENDIX D: MATE Substrates Guidance  ................................................................................ 68 
APPENDIX E: Nivolumab Management Algorithms  .................................................................. 69 
APPENDIX F: Definitions for Adverse Event Reporting ............................................................ 77 
APPENDIX G: Reporting Timelines  ............................................................................................ 79 
APPENDIX H: Washington University Serious Adverse Event Reporting Cover Sheet  ............ 83 
  
Protocol Version:  05/16/2022 – Amendment 7  Page 10 of 83 1 BACKGROUND AND RATIONAL E 
 
1.1 Pancreatic Ductal Adenocarcinoma (PDAC)  
 
The prognosis for patients with pancreatic ductal a denoc arcinoma (PDAC) is dismal, with 
a 5-year overall survival rate o f 8%1. According to the American Cancer Society, an 
estimated 53,670 new cases and 43,090 deaths will occur in the US in 2017. Notably, 
PDAC is projected to be the 2nd leading cause of cancer -related death by [ZIP_CODE]. Due to a 
lack of early warning symptoms and effective screening tools, 85- 90% of PDAC patients 
are diagnosed at advanced  stages when chemotherapy is the only treatment option. The two 
current FDA -approved chemotherapy regimens, FOLFIRINOX and gemcitabine/Nab-
paclitaxel, have improved the median survival of patients with advanced PDAC from about 6.[ADDRESS_1180971] not been successful in PDAC. PDAC tumors are 
characterized by a profound desmoplastic t umor microenvironment (TME)
4. Major 
components of this TME include a  dense fibrotic matrix deposited by c ancer -associated 
fibroblasts (CAFs), and significant infiltration of various subsets of immunosuppressive 
myeloid cells, vascular cells, and nerve cells5-7. Targeting the immunosuppressive myeloid 
cells has recently emerged as a promising approach, with multiple strategies now being developed and t ested. Blocking the CCL2 -CCR2 and CCL5 -CCR2 axe s that drive the 
function of immunosuppressive myeloid cell  function are two examples of these 
approaches. Progression of PDAC is accompanied by [CONTACT_849385]2 and CCL 5, which draw and reprograms circulatory myeloid 
cells and regulatory T cells into deterring anti -tumor T cells
8,9. CCL2 is secreted by [CONTACT_849386]2 positive inflammatory monocytes f rom the bone marrow to the TME 
where they transform to immuno -suppressi ve tumor associated macrophages (TAM) and 
prevent effective anti -tumor immunity10-12. Previous studi es have shown that the ratio of 
bone marrow to blood inflammatory monocytes is prognostic and  inhibition of this axis 
showed responses in preclinical tumor models11,12. Since tumors leverage the CCL2 -CCR2 
and CCL5- CCR5 axis to promote tumor growth through Tregs  and TAM, blocking of this 
axis may be able to overcome the immunosuppressive TME and  
promote effective anti -tumor immunity.  
Protocol Version:  05/16/2022 – Amendment 7  Page 11 of 83  
BMS -813160 (developed by [CONTACT_414]- Myers Squibb)  is an equipotent dual antagonist of 
CCR2 and CCR5 that binds potently to both receptors and exhibits potent dual inhibition 
of in vitro receptor -mediated functions, including  chemotaxis, calcium flux, non-
hydrolyzable guanosine triphosphate analog (guanosine 5’ -3-O- [thio]triphosphate) [GTP -
γS] exchange, and Mac -1 (integrin β ) [CD11 b] upregulation, as well as  CCR5 
phosphorylation and internalization induced by [CONTACT_849387]. BMS -[ADDRESS_1180972] a panel of  other chemokine receptors (C -C chemokine receptor 1 [CCR1], C -C 
chemokine receptor 4 [CCR4], C- X-C chemokine receptor 2 [CXCR2], C -X-C chemokine 
receptor 3 [CXCR3], and  C-X-C chemokine receptor 5 [CXCR 5]) and a panel of G protein-
coupled receptors  (GPCRs)/transporters (21 targets).  
 In CCR2 PD models, BMS -813160 significantly reduced blood monocytes in human 
CCR2  knock- in (hCCR2 KI) mice and increased serum levels of monocyte chemotactic 
protein (MCP) -1 (ligand for CCR2) in hCCR2 KI mice and in monkeys at doses providing 
plasma concentrations that are greater than or equal to the CCR2 binding concentra tion at 
which 90% inhibition is observed (IC90). The compound also reduced blood monocytes in monkeys al though the reduction was not statistically significant due to inter -animal 
variability. Thes e data support the use of these 2 measurements, serum MCP -1 and absolute 
monocyte count, a s CCR2 PD biomarkers in studies of BMS -813160. In CCR5 
homeostatic models in the mouse, preliminary studie s show that BMS -813160 robustly 
inhibited ex vivo- stimulated whole blood (WB) CD11b upregul ation at doses providing 
plasma concentrations that are greater than or equal to the mouse CCR5 binding / CD11b 
IC90. When tested in naïve monkeys for its effect on CCR5 phosphorylation with or 
without ex vivo stimulation and CCR5 internalization with ex vivo stimulus, BMS -813160 
significantly inhibited phosphorylation and internalization at plasma concentrations great er 
than or equal t o the IC90 of CCR5. When studied in 48- hour thioglycollate (TG) peritonitis 
model using hCCR2 KI mice, BMS -813160 substantially reduced monocyte/macrophage 
influx into the peritoneal cavity, providing an estimated in vivo free plasma concentration 
requi red to yield 50% of the maximal response (EC50) value of 4.9 nM, which correlated 
well with the in vitro binding IC50 of 5.8 nM (mouse binding to human peripheral blood 
mononuclear cells [ hPBMCs]). Maximal inhibition of monocyte/macrophage infiltration 
was achieved with approximately 98% receptor occupancy.  
 
BMS -813160 was previously evaluated and found to be relatively safe and well tolerated 
in both healthy participant studies and in participants with diabetic kidney disease (DKD). To date, BMS -[ADDRESS_1180973] one dose of BMS -813160 (108 healthy participants and 59 
participants with diabetic kidney disease). In the single ascending dose study, BMS -813160 
was safe after single dose administrations up to 2000 mg in healthy partici pants 
([STUDY_ID_REMOVED]). There were no deaths, serious adverse events (SAEs) or discontinuations due to AEs. All reported AEs were mild in intensity. At the 2000 mg dose there was an 
increased incidence of CNS -related AEs (dizziness and euphoric mood). Dizzine ss 
occurred in 5 participants (7.1%), all receiving BMS -813160, and all but 1 was considered 
Protocol Version:  05/16/2022 – Amendment 7  Page 12 of 83 by [CONTACT_7185] (n = 1 each in the 150 mg and 1200 mg 
groups, and n = 3 in the 2000 mg group). There were 2 participants in the 2000 mg BMS -
813160 group and 1 participant in the placebo group who had AEs of euphoria. Multiple 
doses of BMS -813160 were safe and generally well tolerated in healthy participants across 
the dose range of 10 to 300 mg QD (N=24) and 300 to 900 mg BID (N=18) f or 14 days. 
There were no deaths, SAEs, or discontinuations due to AEs in this study. AEs were 
reported by 17 (40.5%) participants receiving any dose of BMS -813160 and in 3 (21.4%) 
participants receiving placebo. There was no apparent dose relationship wit h respect to 
AEs. One AE of headache in a participant receiving BMS -813160 10 mg QD was 
considered moderate in intensity. All other AEs were considered to be mild in intensity. 
There were concentration -dependent increases in QRS and PR intervals and HR at 600 mg 
BID and 900 mg BID, without any ECG -related AEs or clinical sequalae. The increases in 
PR (mean < 16 msec at peak), QRS (mean < ~10 msec at peak), and HR (< ~10 bpm at peak) were not considered clinically significant. Concentration- response assessme nt 
showed no QTc prolongation. BMS -813160 was generally safe and well -tolerated when 
administered for 12 weeks. 
 
1.3 Nivolumab (Opdivo)  
 Nivolumab is a fully human, immunoglobulin G4 (IgG4) [kappa] isotype monoclonal antibody that binds to PD -1 with nanomolar affinity (dissociation constant [Kd], 3.06 nM) 
and a high degree of specificity. Nivolumab blocks binding of PD -1 to its ligands PD -L1 
and PD -L2. Nonclinical in vitro testing of nivolumab demonstrated that binding to PD -1 
results in enhanced T -cell prolife ration and release of interferon gamma (IFN γ) in vitro in 
mixed lymphocyte reaction and cytomegalovirus assays. Nivolumb is now approved as 
second line treatment  for sorafenib -resistant hepatocellular carcinoma (HCC) and 
microsatellite -instability -high (MS I-H) colorectal cancer (CRC).  
 
Combination clinical toxicology studies with BMS -813160 and nivolumab is now being 
evaluated in clinical trial ( [STUDY_ID_REMOVED]) for advanced PDAC and CRC. Side effects of 
nivolumab are similar to other anti- PD-1 antibodies and include  pulmonary toxicity, renal 
toxicity (including acute renal failure), endocrine  abnormalities, GI toxicity, dermatologic 
toxicity (including rash), a nd hepatotoxicity. Most high- grade events were manageable 
with the  use of corticosteroids or hormone replacement therapy (endocrinopathies). There 
is no relationship between the incidence, severi ty, or causality of AEs and the nivolumab 
dose level.  
 
Nivolumab 480 mg every 4 weeks (Q4W) is currently under active clinical evaluation 
across  multiple tumor ty pes ([STUDY_ID_REMOVED]) . Using a PPK model, nivolumab 480 mg 
Q4W is predicted to provide average steady -state concentrations (Cavgss) similar to 
nivoluma b 3 mg/kg Q2W. Nivolumab 480 mg Q4W is predicted to provide greater 
(approximately 40%) Cmaxs s and lower (app roximately 20%) trough steady -state 
concentrations (Cminss). Nivolumab has  been shown to be safe and well tolerated up to 
doses of 10 mg/kg Q2W and has not demons trated a clear dose response or exposure -
response safety relationship. Based on these safety f indings, the predicted Cmaxss at 480 
mg Q4W is not considered to put patients at increased risk for AEs. The approved doses of 
Protocol Version:  05/16/2022 – Amendment 7  Page 13 of 83 3 mg/kg Q2W and [ADDRESS_1180974] shown survival benefit across multiple tumor ty pes 
compared to respective standards of care. Nivolumab exposure was  not a predictor of 
survival in exposure response efficacy analyses conducted for multiple  tumor types.  
  
Clinical evaluation of 480mg Q4W is ongoing; as such, summaries of safety information, PK, and immunogenicity are not currently avai lable.  
 
1.4 Summary of common or signific ant side effects for each agent  
 
BMS -813160:  Headache, dizziness, diarrhea, abnormal liver function, impaired wound 
healing, EKG changes (mild prolongation of QRS and PR at > 600mg BID was observed 
but not considered clinically -significant. Not expected to occur at 300mg BID as proposed 
in our study ). 
 
Nivolumab:  infusion reaction, fatigue, diarrhea, immune -related toxicities including 
pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, dermatitis, encephalitis.  
 
Gemcitabine:  infusion reaction, nausea/vomiting, anorexia, flu- like symptoms,  fatigue, 
peripheral edema, myelosuppression, abnormal liver function, abnormal kidney function, 
hemolytic uremic syndrome, pneumonitis, capi[INVESTIGATOR_12737], posterior reversible encephalopathy syndrome.  
 
Nab-paclitaxel:  infusion reaction, hypersensiti vity, nausea/vomiting, fatigue, peripheral 
edema, peripheral/sensory neuropathy, abnormal liver function, abnormal kidney function, 
myelosuppression, pneumonitis, abnormal EKG, alopecia, rash, anorexia.  Overlappi[INVESTIGATOR_50685]:  Pneumonitis, abnormal liver function, abnormal kidney function, 
EKG changes, myelosuppression. 
 
Additional potential toxicities:  We expect the majority of the acute side effects to be 
cause by [CONTACT_11553]. However, the combination of BMS -813160, nivolumab, 
gemcitabine and nab -paclit axel may increase the risk for fatigue, diarrhea, pneumonitis and 
abnormal liver function based on overlappi[INVESTIGATOR_50685]. These will be monitored for during 
each clinical visit and dose- adjustments will be performed per protocol.  
 
1.[ADDRESS_1180975] pancreatic ductal 
adenocarcinoma (PDAC) is a significant unmet medical need. One promising way to 
improve outcomes for patients with PDAC is to alter the tumor immune microenvironment to support therapeutic responses. Acute immune responses involving CD8
+ cytotoxic T 
lymphocytes (CTLs) and/or natural killer cells can effectively restrain tumor development and progression. Indeed, the few durable responses to therapy observed in PDAC are often 
associated with maintenance of the anti- tumor CTL activity that kills remnant tumor cells 
following therapy
5,13. Unfortunately, to date, immunotherapy has struggled to achieve 
signif icant clinical benefit when used as a single therapeutic agent in PDAC3. This is likely 
Protocol Version:  05/16/2022 – Amendment 7  Page 14 of 83 due to the presence of an immunosuppressive tumor microenvironment. Critical drivers of 
this immunosuppressive microenvironment are tumor -infiltrating inflammatory monocytes 
(IMs), tumor -associated macrophages (TAMs), and immature granulocy tes14-17. In addition 
to instigating immune suppression, these tumor -infiltrating leukocytes impart resistance to 
cytotoxic therapi[INVESTIGATOR_93809] d promote metastatic dissemination18-20. Thus, high numbers of these 
cells correlate with early metastatic relapse and p oor PDAC survival5,21- 23. Therefore, 
approaches that reprogram the tumor microenvironment to potentiate protective anti -tumor 
immunity hold significant therapeutic potential.  
 
We and other groups have demonstrated that mobilization and tumor infiltration of IMs and TAMs can promote tumor growth, dissemination, local immunosuppression, and 
resistance to cytotoxic therapy
5,18,23 -25. Signaling through C -C chemokine receptor type 2 
(CCR2) is critical for the mob ilization of IMs and their recruitment to inflamed tissues. 
Our recently published reports clearly illustrate that blockade of IM recruitment using CCR2 inhibitors (CCR2i), slows tumor progression, improves responses to chemotherapy, 
and prevents metastasi s in mouse models of PDAC
5,23. Based on these data, we initiated 
an early phase clinical tr ial targeting the CCR2 signaling pathway in patients with locally 
advanced PDAC. In this trial ([STUDY_ID_REMOVED]), we have observed a remarkable 48.5% 
response rate in the 33 patients treated with CCR2i + FOLFIRINOX. This regimen was 
also well tolerated. Observ ed clinical responses correlate with a marked reduction in 
CCR2+ IMs and TAMs in patient tumor tissue. In contrast, CCR2i + FOLFIRINOX 
significantly increased effector T cell infiltration and anti- tumor cytokines, suggesting that 
CCR2 inhibition overcomes the suppressive tumor microenvironment. Paralleling these 
clinical data, our published preclinical studies found that CCR2 blockade reinitiates anti -
tumor responses by [CONTACT_398]8+ CTLs5,23. Intriguingly, we have discovered that CCR2 blockade 
in both human patients and mouse models leads to the up- regulation of T cell checkpoint 
pathways, including programmed cell death- 1 (PD1) and its ligands (PDL1 and PDL2). In 
addition, additional targeti ng of CCL5- CCR5 should further blunt regulatory T cell 
response thereby [CONTACT_849388] T cells9. These data suggest that 
we might find unique therapeutic synergy between dual CCR2 /[ADDRESS_1180976] 1.1 criteria. 
Objective response rate (ORR) is defined as partial response plus complete response. 
Resectability will be assessed by [CONTACT_849389], surgeons,  and radio logists. 
Because this study enrolled patients with borderline resectable or locally advanced PDAC, endoscopic ultrasound- guided t umor biopsies will be performed at two different time 
points: less than 2 weeks before C ycle 1 Day 1 of treatment  (pre-treatmen t), and within 2 
weeks aft er Cycle 2 Day 15 of treatment (post -treatment).   
 
Protocol Version:  05/16/2022 – Amendment 7  Page 15 of 83 Exploratory studies will be performed on the paired biopsied samples and include the 
following :  
 
1. Peripheral and intra- tumoral CCR2 monocytes. Analyses of PB and tumor will be  
performed using flow cytometry as published23. We are particularly interested in changes 
in the number of IMs, which were predictive of survival in our published data23.  
 
 2. Analyses of antigen- specific T lymphocytes in the periphery.  Alterations in peripheral 
lymphocyte  frequency will be determined with flow cytometry. To assess T lymphocyte 
functionality in PB, we will evaluate proliferation and cytokine profiles following 
polyclonal and/or PMA activation ex vivo. We will compare polyclonal activation of total 
PB (inclu ding IMs) to isolated CD4+ and CD8+ T cells. We will also examine the 
responsiveness of T lymphocytes to three common PDAC antigens, including mesothelin
26,27, MUC128, and CEA29 using peptide stimulation of PBMCs, followed by 
[CONTACT_15236]30 and MHC Dextramers responsiveness (IMMUDEX). Results will be compared 
to the non- tumor antigen responses to CMV. Analyses  will be performed using a BD 
LSRFortessa -X20 (up to 20- color analysis). Based on the observed reprogramming of the 
tumor microenvironment10, we anticipate that the proposed regimen will improve T cell 
responsiveness and/or cytokine production in response to tumor -specific antigens. If this is 
not observed, we will conclude that CCR2 blockade affects the activity of T cells in the tumor microenvironment rather than regulati ng systemic immune suppression. 
 
3. Changes in the tumor immune microenvironment that facilitate T cell responses. We 
have developed t echniques to routinely  run both gene expression and flow cytometry on 
very limited amounts of tissue from EUS -guided FNAs or core biopsies. To assess changes 
in the tumor microenvironment, we will employ these techniques on samples from both clinical trials to assess how these therapi[INVESTIGATOR_849361]. 
  
3a Cellular immune infiltrate:  Using pre - and post -treatment core biopsies, we will directly 
assess how CCR2i therapi[INVESTIGATOR_849362] -infiltr ating immune populations using high -
density flow cytometry. We have optimized these protocols to assess T cells, myeloid cells, and DC subsets and activation markers in three 15 -color flow cytometry. Using this we fill 
focus on three questions:  
1. How does C CR2i -based therapy impact the number, activation, proliferation, and 
checkpoint expression of tumor -infiltrating T cells?  
2. How does CCR2i -based therapy alter the spectrum of tumor -infiltrating myeloid 
cells, including monocytes, macrophages, and granulocyt es? 
3. How does CCR2i -based therapy impact the number and phenotype of tumor -
infiltrating antigen -presenting cells, such as dendritic cells and macrophages?  
4. Does CCR2i -based therapy lead to the upregulation of checkpoint or other 
molecules of immunotherapeutic opportunity (such as LAG3 on T cells or CD40 on innate immune cells)?  
 
3b Tumor cytokine microenvironment:  We will analyze gene expression in tumor tissue 
following pre -amplification using two Taqman -based qRT -PCR arrays. We have designed  
Protocol Version:  05/16/2022 – Amendment 7  Page 16 of 83 these arrays to contain 180 cytokines, immune effector, and checkpoints molecules. These 
analyses will yield information regarding alterations in the cytokine microenvironment, 
immunosuppression, and potential new targets for combined immunotherapy.  
 
 
2 OBJECTIVES  
 
2.1 Primary Objectives  
 
1. Part A: To determine the safety of the combination of BMS -813160 plus nivolumab 
plus gemcitabine plus nab- paclitaxel.  
2. Part B: To determine the objective response rate of patients with locally advanced and 
borderline -resectable pancreatic ductal adenocarcinoma treated with the combination 
of BMS -813160 plus nivolumab plus gemcitabine plus nab- paclitaxel.  
 
2.2 Secondary Objectives  (Part B)  
 
1. To determine the percentage of patients with locally advanced and borderline resectable 
pancre atic ductal adenocarcinoma treated with the combination of BMS -813160 plus 
nivolumab plus gemcitabine plus nab- paclitaxel w hose disease becomes resectable 
after treatment.  
2. To determine the progression- free survival (PFS) of patients with locally advanced and 
borderline resectable pancreatic ductal adenocarcinoma treated with the combination of BMS -813160 plus nivolumab plus gemcitabine plus nab- paclitaxel.  
3. To determine the overall survival (OS) of patients with locally advanced and borderline resectable pancreatic ductal adenocarcinoma treated with the combination of BMS -
813160 plus nivolumab plus gemcitabine plus nab -paclitaxel.  
 
2.3 Exploratory Objectives (Parts A and B)  
 
1. To determine the prevalence and function of inflammatory monocytes in the peripheral blood and tumor of patients with locally advanced and borderline resectable pancreatic 
ductal adenocarcinoma before and after treatment with the combination of BMS -
813160 plus nivolumab plus gemcitabine plus nab -paclitaxel.  
2. To compare the difference in the im mune cell infiltration and cytokine expression in 
the biopsied tumors of patients with locally advanced and borderline resectable 
pancreatic ductal adenocarcinoma before and after treatment with the combination of 
BMS -813160 plus nivolumab plus gemcitabine  plus nab- paclitaxel.  
3. To correlate changes in the immune infiltrate with clinical responses to treatment with 
the combination of BMS -813160 plus nivolumab plus gemcitabine plus nab- paclitaxel 
and survival following treatment with that combination. 
4. To compa re results of inflammatory monocyte, analysis, immune cell infiltration and 
cytokine expression analysis, and correlation of immune infiltrate with clinical 
response from patients enrolled to the experimental arm with results of analyses from 
patients enro lled to the control arm (if feasible and depending on the results) . 
 
Protocol Version:  05/16/2022 – Amendment [ADDRESS_1180977] adenocarcinoma before being treated on study.  Patients with 
squamous carcinoma , adenosquamous carcinoma  or neuroendocrine tumor  will be 
excluded.  Tumor Biopsy can be omitted, if deemed by [CONTACT_976] [INVESTIGATOR_315226], that 
it may incur immediate, excessive health risks to patients. This determination (rationale and discussion with PI [INVESTIGATOR_315226]) should be clearly documented in the 
screening visit notes.  
 
2. Measurable disease defined as lesions that can be accurately measured in at least one 
dimension (longest diameter to be recorded) as ≥ [ADDRESS_1180978] 18 years of age.  
 
4. ECOG performance status ≤  1 (see Appendix A ) 
 
5. Normal bone marrow and organ function as defined below:  
a. Leukocytes  ≥ 2,000/mcL  
b. Absolute neutrophil coun t ≥ 1,500/mcl  
c. Hemoglobin ≥ 8.5 g/dL  
d. Platelets ≥ 100,000/mcl  
e. Total bilirubin  ≤ 1.[ADDRESS_1180979]  (except participants with Gilbert’s Syndrome who 
must have normal direct bilirubin)  
f. AST(SGOT)/ALT(SGPT)  ≤ [ADDRESS_1180980]  
g. Serum albumin  ≥ 3g/dL  
h. Creatinine ≤ 1.[ADDRESS_1180981]  OR creatinine clearance ≥ 40 mL/min by [CONTACT_3158] -Gault 
for patients  with creatinine levels abo ve institutional normal 
 
6. Women of childbearing potential and men must agree to use at least two forms of 
contraception (hormona l, barrier method of birth control, abstinence , and must include 
barrier method ) prior to study entry , for the duration of study participation , and through 
5 months  (for women) or 7 months (for men)  after the last dose of treatment on this 
study .  Should a woman become pregnant  or suspect she is pregnant while participating 
in this study, she must  inform her treating physician immed iately.  
 7. Able to understand and willing  to sign a n IRB approved written informed consent 
document. 
 
8. All toxicities attributed to prior anti- cancer therapy other than alopecia and fatigue must  
have resolved to Grade 1 (National Cancer Institute Common Termi nology Criteria for  
Adverse Events [NCI CTCAE] v5.0) or baseline before administration of study 
Protocol Version:  05/16/2022 – Amendment 7  Page 18 of 83 treatment.  Participants with toxicities attributed to prior anti- cancer therapy that are not 
expected to  resolve and result in long lasting sequelae, such as ne uropathy after 
platinum -based  therapy, are permitted to enroll.  
 
3.2 Exclusion Criteria  
 
1. Prior exposure to chemotherapy or radiation for the disease to be treated on this trial  
not allowed. 
 
2. Previous malignancies (except non -melanoma skin cancers, and in situ  bladder, gastric,  
colorectal, endometrial, cervical/dysplasia, melanoma, or breast cancers) unless a 
complete  remission was achieved at least 2 years prior to study entry AND no 
additional therapy is  required during the study period. Other active malignan cy 
requiring concurrent intervention 
 3. Currently receiving any other investigational agents , or exposure to any investigational 
drug or placebo within 4 weeks of study treatment  
 4. A history of allergic reactions attributed to compounds of similar chemical or  biologic 
composition to BMS -813160, nivolumab, gemcitabine, paclitaxel, nab- paclitaxel, or 
other agents used in the study.  
 5. Prior exposure to anti -PD-1, anti -PD-L1, CCR2/5, or anti -CTLA4 antibodies. 
 6. Taking immunomodulatory agents (including steroids and NSAIDs) .  A wash -out 
period of at least 4 weeks or 5 half -lives, whichever is shorter, is required for patients 
receiving immunomodulatory agents at the time of enrollment.   
 
NOTE: daily use of low dose aspi[INVESTIGATOR_248] (e.g. 81 mg PO QD) is not considered an 
immunomodulatory agent and patients are still eligible for enrollment despi[INVESTIGATOR_849363] a low dose. 
 
7. Participants with active, known or suspected autoimmune disease. Participants with 
vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition 
only requiring hormone replacement, euthyroid participants with a history of Grave’s 
disease (participants with suspected autoimmune thyroid disorders must be negative for thyroglobul in and thyroid peroxidase antibodies and thyroid stimulating 
immunoglobulin prior to first dose of study treatment), psoriasis not requiring systemic 
treatment, or conditions not expected to recur in the absence of an external trigger are 
permitted to enro ll after discussing with th e Principal Investigator  
 8. Participants with a condition requiring systemic treatment with either corticosteroids 
(> 10 mg daily prednisone or equivalent) or other immunosuppressive medications 
within 14 days of study treatment ex cept for adrenal replacement steroid doses > 10 
mg daily prednisone equivalent in the absence of active autoimmune disease.  Note: 
Protocol Version:  05/16/2022 – Amendment 7  Page 19 of 83 treatment with a short course of steroids (< 5 days) up to 7 days prior to initiating study 
treatment is permitted.  
 
9. History of allogeneic organ or stem cell transplant.  
 
10. Pregnant  and/or breastfeeding.  Women of childbearing potential  must have a negative 
pregnancy test within [ADDRESS_1180982] 
treatment.  
 
11. Known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known active hepatitis C virus ( by [CONTACT_954]) . 
 
12. Known history of testing positive for human immunodeficiency virus (HIV) or known  
acquired immunodeficiency syndrome. Anti -retroviral agents are known to have 
potential adverse pharmacokinetic interactions with nivolumab and/or BMS -813160. 
IN addition, patients not on anti -retroviral agents, regardless of HIV viral load, are at 
increased risk of lethal infections with marrow -suppressive therapy including  
chemotherapy.  Testing for HIV must be performed at sites  mandated by [CONTACT_2243].  
 
13. Requires continued use of warfarin for anticoagulation and cannot stop warfarin or be safely switched to another anticoagulant.  
 14. Current or recent (within 3 months of study treatment administration) g astrointestinal 
disease or conditions  that could interfere with the swallowing or absorption of study 
medication  or inability to tolerate oral medication . 
 
15. Uncontrolled intercurrent illness including, but not limited to, ongoing or active 
infection  requiring parenteral anti -bacterial, anti -viral, or anti -fungal therapy ≤ 7 days 
prior to administration of study medication; immunosuppression;  autoimmune 
conditions ; underlying pulmonary disease ; or psychiatric illness/social situations that 
would limit compliance with study requirements.  
 
16. Interstitial lung disease that is symptomatic or may interfere with the detection or 
management of suspected treatment -related pulmonary toxicity.  
 17. Uncontrolled or significant cardiovascula r disease including, but not limited to, any of 
the following:  
a. Myocardial infarction or stroke/transient ischemic attack within the past [ADDRESS_1180983] 3 months  
c. Any history of clinically significant arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes)  
d. QT interval corrected for heart rate using Fridericia’s formula (QTcF) prolongation 
> 480 msec  
Protocol Version:  05/16/2022 – Amendment 7  Page 20 of 83 e. History of other clinically significant heart disease (e.g. cardiomyopathy, 
congestive heart  failure with NYHA functional classification III -IV, pericarditis, 
significant pericardial effusion, or myocarditis)  
 
18. Major surgery within [ADDRESS_1180984] dose of study treatment.  
 
19. Concurrent use of oral or intravenous medications , or food which may interfere with 
BMS -813160 including any strong inhibitors or inducers of CYP3A4 or P -gp is not 
allowed (see Appendix C). These include but are not limited to Class I antiarrhythmics 
(eg, quinidine, procainamide, dysopi[INVESTIGATOR_163361], lidocaine, phen ytoin, mexiletine, 
tocainide, flecainide, propafenone, moricizine), Grapefruit and Seville oranges.  
 
3.[ADDRESS_1180985] be taken before registering patients to this study:  
 
1. Confirmation of patient eligibility by [CONTACT_2370]  
2. Registra tion of patient in the Siteman Cancer Center database  
3. Assignment of unique patient number (UPN)  
 Once the patient has been entered in the Siteman Cancer Center OnCore database, the WUSM 
coordinator will forward verification of enrollment and the UPN via em ail. 
 
4.[ADDRESS_1180986] one business day prior to 
registering patient:  
 
1. Your name  [CONTACT_3669] [CONTACT_3031] ( telephone number, fax number, and email 
address ) 
2. Your site PI’s name , the registering MD’s name, and your institution name  
3. Patient’s race, sex, and DOB  
4. Three letters (or two letters and a dash) for the patient’s initials  
5. Currently approved protocol version date  
Protocol Version:  05/16/2022 – Amendment 7  Page 21 of 83 6. Copy of signed consent form (patient name [CONTACT_205192])  
7. Planned date of enrollment 
8. Completed eligibility checklist, signed and dated by a member of the study team  
9. Copy of appropriate source documentation confirming patient eligibility  
 
4.[ADDRESS_1180987]. Urg ent 
late afternoon or early morning enrollments should be planned in advance and coordinated 
with the Washington University research coordinator.  Registration will be confirmed by [CONTACT_205978]/her delegate by [CONTACT_849390] d ay. Verification 
of eligibility and registration should be kept in the patient chart.  
 All p atients at all sites must be registered through the Siteman Cancer Center OnCore 
database at Washington University.  
 
4.3 Assignment of UPN  
 Each patient will be identified with a unique patient number (UPN) for this study.  Patients will also be identified by [CONTACT_22705], middle, and last initials.  If the patient has no middle initial, a dash will be used on the case report forms (CRFs).  All data will be recorded with this 
identification number on the appropriate CRFs. 
  
[ADDRESS_1180988] 16 patients will be randomized 1:1  to the control arm  (where pat ients will 
receive chemotherapy only) or  the experimental arm  (where patients will receive BMS -813160 
plus nivolumab plus chemotherapy).  Randomization will stop after [ADDRESS_1180989] been enrolled and 
treated on the control arm, subsequent patients will be enrolled only into the experimental arm (up 
to 18 patients total including the patients previously randomized to the experimental arm) or in the expansion phase if MTD (or recommended phase II dose, RP2D) has been determined. Th ese [ADDRESS_1180990] of 
gemcitabine plus nab -paclitaxel plus  BMS -813160 and nivolumab.  For patients randomized to 
the experimental arm, treatment will start at dose level 0 ( refer to Section 5.2).  Enrollment in the 
experimental arm will continued until an MT D is determined , which may require up to [ADDRESS_1180991] 3+ [ADDRESS_1180992] 3 
subjects, if ≥ 2 subjects experience DLTs, dose de -escalation will be performed, and three new 
subjects will be enrolled. All p atients already on the starting dose  will resume treatment af ter 
recovery from previous  toxicities , or continue on treatment  at the new dose- deescalated level. Nine 
to 18 patients may be needed to determine an MTD if one or more dose de -escalation is warranted.  
Protocol Version:  05/16/2022 – Amendment 7  Page 22 of 83  
After the MTD of BMS -813160 and chemotherapy  has been  determined in Part A  (or the RP2D) , 
more patients will be enrolled at that dose level for a  total of [ADDRESS_1180993] -treatment biopsy will be performed after 2 cycles of treatment, followed by 
a restaging scan ( pancreatic protocol CT or MRI). Patients who have disease progression per 
RECIST 1.[ADDRESS_1180994] two years and per the physician’s discretion beyond two years . 
Participants who withdraw from the study during the DLT evaluation interval for reasons other 
than a DLT may be replaced at the same dose of BMS -813160. 
 Patients with progressive disease or patients whose disease is not considered resectable after treatment will receive other treatments off study as determined by [CONTACT_86297].  If 
deemed appropriate, patients may continue to be treated with gemcitabine and/or nab- paclitaxel.   
Patients whose disease is considered resectable will undergo surgical re section off study (with 
specimens collected as part of this study).  
 Treatment beyond radiographic disease progression per initial RECIST v 1.[ADDRESS_1180995] participants after discussion and agreement with the PI  [INVESTIGATOR_849364]/risk assessment favors continued administration of study treatment. These include: good 
tolerance of study treatment, stable performance status, treatment beyond progression will not 
delay an imminent intervention to prevent serious  complications of disease progression (e .g., CNS 
metastases). These are considered investigator -assessed clinical benefit and must be clearly 
documented i n clinic notes.  
 
5.1 Agent Administration  
 
BMS -813160 is an oral drug which will be given at the assigned dose  twice (or once) daily 
for patients in Part A assigned to the experimental arm and all patients in Part B.  If a 
patient misses a dose  and the next scheduled dose is within the next 8 hours (or within the 
next 16 hours  if being taken once daily) , s/he should not make up that dose but simply 
resume dosing with the next scheduled dose.  Therefore, patients should make up for the 
missed BMS -[ADDRESS_1180996]  
(16 hours if once daily) . If a patien t should vomit  within one hour after intake, s/he should 
make up for that dose  as long as the next scheduled dose is more than [ADDRESS_1180997]  (16 
hours if once daily) . Patients will be instructed to bring all unused drug and their medication 
diary (Appendix B) to each study visit for an assessment of compliance.  
 
Protocol Version:  05/16/2022 – Amendment 7  Page 23 of 83 Nivolumab will be given as a 30 -minute intravenous infusion at a flat dose of 480 mg on 
Day 1 (+/- 2 days) of each 28- day cycle  for patients in Part A assigned to the experimental 
arm and all patient s in Part B . 
 
Gemcitabine will be given as a 30 -minute intravenous infusion at the assigned dose ( for all 
patients in Part A) or at the MTD ( for all patients in Part B) on Days 1, 8, and 15 of each 
28-day cycle.  A window of +/ - [ADDRESS_1180998] results (see Section 6.3) and clinical assessment of patients by [CONTACT_44375]. On days when both nivolumab and gemcitabine are given, a [ADDRESS_1180999] is 
required between nivolumab and gemcitabine.  
 
Nab-paclitaxel will be given as a 30 -40-minute intravenous infusion at the assigned dose 
(for all patients in Part A) or at the MTD ( for all patients in part B) on Days 1, 8, and 15 of 
each 28 -day cycle.   A window of +/ - [ADDRESS_1181000] results (see Section 6.3) and clinical assessment of patients by [CONTACT_512883].  
 5.2 Dose De -Escalation Schema  – Part A  
Part A: Safety Lead -In (Each cycle = 28 days)  
Arm (by 
[CONTACT_17628])  BMS -813160  (D1-28) Nivolumab 
(D1)  Chemotherapy  (D1, 8, 15)  
Dose Level  Dose  Dose Level  Gemcitabine  Nab-paclitaxel  
Experimental 
(n=9- 18) 0 (starting)  300 mg BID  480 mg  0 (starting)  1000 mg/m2 125 mg/m2 
-1 150 mg  BID  480 mg  -1 800 mg/m2 100 mg/m2 
-2 150 mg  QD  480 mg  -2 600 mg/m2 75 mg/m2 
Control (n=8)  N/A N/A N/A 0 (starting)  1000 mg/m2 125 mg/m2 
N/A N/A N/A -1 800 mg/m2 100 mg/m2 
N/A N/A N/A -2 600 mg/m2 75 mg/m2 
Part B: Dose Expansion (Each cycle = 28 days)  
Dose expansion 
(N=30 *)  Per Part A  480 mg   Per Part A 
* Total of 30 patients includes patients started on and stayed on MTD on experimental arm in Part A  
  
5.3 Definition of MTD, DLT, and  Dose Escalation Criteria  – Part A  
 
5.3.1 Definition of Max imum Tolerated Dose (MTD)  
 
The maximum tolerated dose (MTD) is defined as the dose level at which [ADDRESS_1181001] cycle  (28 
days) . Dose de -escalations will proceed until the MTD has been reached.  This will 
be the r ecommended phase II dose (RP2D)  for Part B and any future clinical trials.   
 
5.3.2 Dose Limiting Toxicities (DLTs)  
 
For the purpose of guiding dose regimen, DLTs will be defined based on the incidence, duration, and grade of AEs for which no alternate cause can be 
identified. Adverse events will be evaluated according to the NCI CTCAE v 5.0. 
The incidence of DLT(s) during the first  cycle (28 days)  of treatment in Part A (the 
Protocol Version:  05/16/2022 – Amendment 7  Page 24 of 83 DLT evaluation period) will be used. Every attempt must be made to assign 
relationship to BMS -813160, nivolumab, chemotherapy or to all. Toxicities that are 
well recognized and expected with the chemotherapy backbone , as determined by 
[CONTACT_849391] [INVESTIGATOR_158814], will not be counted as dose limiting  for the 
entire regimen if the pati ent is on experimental arm . Also, to meet criteria for dose 
limiting, AEs have to be related to study treatment and not to disease progression  
or known common complications from the disease , be clinically relevant , and be a 
clinically relevant shift from b aseline (see Section 6) . Consideration will be given 
to a participant’s ability to tolerate the regimen during the safety lead-in phase. 
Participants experiencing a DLT may be treated at one dose reduction  of BMS -
813160 and/or chemotherapy  as long as they recover from the toxicity  and do not 
meet discontinuation criteria, and  as long as it  is in the best interest of the participant 
per the treating physician , and after discussion with the Principal Investigator [INVESTIGATOR_849365] a DLT may be replaced at the same dose of BMS -
813160. 
 Continue to monitor all patients for approximately [ADDRESS_1181002] cycle that are attributed as possibly, probably, or definitely related to the study treatment:  
• Grade 4 neutropenia (ANC < 500 cells/mm
3) > 7 consecutive days without 
growth factor support  
• Febrile neutropenia of any duration with temperature ≥ 38.5 °C  
• Grade 4 anemia regardless of duration 
• Grade 2 or above thrombocytopenia (platelets < 75 ,000/mm3)  
 Non-hematologic DLT is defined as any possibly, probably, or definitely related 
grade [ADDRESS_1181003] cycle with 
the following specific exceptions:  
• Grade 3 diarrhea that responds to optimal antidiarrheal therapy  
• Grade 3 nausea or vomit ing that responds to optimal antiemetic therapy  
• Grade [ADDRESS_1181004] two separate ECGs , which are 
corrected by [CONTACT_849392], not complicated by [CONTACT_849393]  
• Grade 3 increase in total bilirubin that improve s within 48 hours.  
• Grade [ADDRESS_1181005] less than 48 hour s and either 
resolve  spontaneously or respond to conventional medical intervention  
• Isolated Grade 3 or 4 elevation of amylase or lipase not associated with 
clinical or radiographic evidence of pancreatitis  
Protocol Version:  05/16/2022 – Amendment 7  Page 25 of 83  
Other events that are considered DLTs are:  
• Autoim mune hypophysitis (any grade)  
• Persistent (>4 weeks) unresolved grade≥3 hepatitis  not corrected by 
[CONTACT_849394], adjustment of medications  and 
strongly suspected to be related to nivolumab, BMS -8313160 or 
chemotherapy.   
• Pneumonit is (at least grade 2)  
Any toxicity that is possibly, probably, or definitely related to study 
treatment that results in failure to receive at least approximately 75% of the 
planned doses of BMS -813160 during Cycle 1 (e.g. failure to complete at 
least 21 days of treatment in a continuous 28- day regimen) despi[INVESTIGATOR_849366] a DLT.  
 
5.3.3 Dose De -escalation Criteria  
 
Dose de-escalations will proceed as follows after the occurrence of dose- limiting 
toxicity (DLT) . Dose de -escalation of BMS813160 and/or chemotherapy should be 
conducted separately based on consideration of DLTs contributed individually by 
[CONTACT_170149] (see Section 6).  
 
Number of Patients 
with DLT at a 
Given Dose Level   
De-Escalation Decision Rule  
0 out of 3  Stop de -escalation. This is defined as RP2D.  
1 out of 3  Treat 3 more patients at the dose level.  
 
• If 0 of these 3 experiences DLT, then stop de -escalation.  
 
• If 1 or more experience DLT, then proceed to the next dose 
level.  
>=[ADDRESS_1181006] receiving study treatment until a 100- day follow up after the 
conclusion of treatment or death.  
 All patients are evaluable for disease response unless they discontinue treatment  due to 
treatment related adverse events(s) prior to completion of C ycle [ADDRESS_1181007] not had any 
disease assessment.  
 A patient is evaluabl e for DLT assessment only if enrolled to the experimental arm during 
Part A of the study and only during Cycle 1  of treatment.  If the patient is not able to be 
treated on Day 1  of Cycle 2 , then s/he is  still considered in C ycle 1 active treatment and 
Protocol Version:  05/16/2022 – Amendment 7  Page 26 of 83 will continue to be evaluated for  DLT.  Once the patient has been treated in C ycle 2, s/he 
will no longer be evaluated for DLTs in all subsequent cycles.   
 
5.5 Part B – Dose Expansion  
 
After the MTD is determined in Part A, additional patients will be enrolled in  Part B to 
reach a total of 30 patients treated at the MTD dose level  (including part A)  
 
5.6 General Concomitant Medication and Supportive Care Guidelines  
 
Supportive care will be administered as per routine practice. This typi[INVESTIGATOR_849367], and antiemetic medication for symptoms of nausea or 
emesis. Intravenous fluid support will be provided at the discretion of the treating physician 
for patients who experience significant nausea, emesis, or diarrhea.  For grade 3 or gr eater 
skin toxicity, dermatology consult is recommended.  Oral antibiotics (such as minocycline or doxycycline should be considered at any sign of rash.  Topi[INVESTIGATOR_849368].  
 Prohibited and/or restricted m edications taken prior to study treatment administration in 
the s tudy are described below. Medications taken within [ADDRESS_1181008] be recorded on the CRF.  
• In vitro, the metabolism of BMS -813160 was primarily mediated via cytochrome 
P450(CYP) 3A4, with some contribution from CYP3A5, and BMS -813160 was 
also a substrate for P -glycoprotein (P -gp). Based on these results, the potential 
exists for drug -drug interaction if BMS -813160 is co- administered with inhibitors 
or induc ers of CYP3A or P -gp. Therefore , use of any oral or intravenous strong 
inhibitors or inducers of CYP3A4 or P -gp is not allowed, but topi[INVESTIGATOR_535169] 
(see Appendix C ). 
• Grapefruit and Seville oranges and their juices can inhibit CYP3A4 and should not be consumed while on study.  
• Caution is warranted with concomitant use of MATE1 substrates with a narrow therapeutic index (see Appendix D ). 
• Exposure to any investigational drug or placebo within 4 weeks of study treatment  
• administration.  
• Class I antiarrhythmics (eg, quinidine, procainamide, dysopi[INVESTIGATOR_163361], lidocaine, 
phenytoin, mexiletine, tocainide, flecainide, propafenone, moricizine).  
• In limited circumstances (eg, life threatening illness) the use of the above 
medications may be permitted.  
 
5.7 Women  of Childbearing Potential  (WOCBP)  
 
Women of childbearing potential are defined as women with regular menses , women with 
amenorrhea, women with irregular cycles, women using a contraceptive method that 
precludes withdrawal bleeding , and w omen who have had a tubal ligation ). A woman is 
considered fertile following menarche and until becoming post -menopausal unless  
permanently sterile. Permanent sterilization methods include hysterectomy, bilateral 
Protocol Version:  05/16/2022 – Amendment 7  Page 27 of 83 salpi[INVESTIGATOR_1656], and bilateral oophorectomy. Documentation can come from the site 
personnel’s review of the participant’s medical  records, medical examination, or medical 
history interview. A postmenopausal state is defined as [ADDRESS_1181009] a serum follicle stimulating hormone, 
(FSH) level> 40 mIU/mL to confirm menopause.  WOCBP  are required to have a negative 
pregnancy test within [ADDRESS_1181010] treatment, and every 4 weeks while on treatment  
 Male participants with female partners of childbearing potential are eligible to participate if they  agree to the following during the treatment and until the  end of relevant systemic 
exposure. 
• Inform any and all partner(s) of their participation in a clinical drug study and the need to  comply with contraception instructions as directed by [CONTACT_093]. 
• Male participants are required to use a condom for stu dy duration and until end of 
relevant  systemic exposure defined as 7 months after the end of study treatment. 
• Female partners of males participating in the study to consider use of effective methods of  contraception until the end of relevant systemic expos ure, defined as 7 
months after the end of  treatment in the male participant.  
• Male participants with a pregnant or breastfeeding partner must agree to remain 
abstinent from  penile vaginal intercourse or use a male condom during each epi[INVESTIGATOR_849369] 7 months after the end of study 
treatment.  
• Refrain from donating sperm for the duration of the study treatment and until 7 months after  the end of study treatment.  
 
Female and male patients (along with their female part ners) are required to use two forms 
of acceptable contraception, including one barrier method, during participation in the study 
and for 5 months  (for women) or 7 months (for men)  following the last dose of study 
treatment . Should a woman become pregnant or suspect she is pregnant while participating 
in this study, she must inform her treating physician immediately.  
 
If a patient is suspected to be pregnant, study treatment should be immediately 
discontinued.  In addition, a positive urine test must be conf irmed by a serum pregnancy 
test.  If it is confirmed that the patient is not pregnant, the patient may resume dosing.  
 If a female patient or female partner of a male patient becomes pregnant during therapy or within [ADDRESS_1181011] be notified in 
order to facilitate outcome follow -up. 
 
5.8 Duration of Therapy  
 
If at any time the constraints of this protocol are considered to be detrimental to the 
patient’s health and/or the patient no longer wishes to c ontinue protocol therapy, the 
protocol therapy should be discontinued and the reason(s) for discontinuation documented 
in the case report forms.  
Protocol Version:  05/16/2022 – Amendment 7  Page 28 of 83  
In the absence of treatment delays due to adverse events, treatment may continue for  a total 
of 4 cycles  or until  one of the following criteria applies:  
 
• Documented and confirmed disease progression  
• Death  
• Adverse event(s) that, in the judgment  of the investigator, may cause severe or 
permanent harm or which rule out continuation of study drug 
• General or specific changes in the patient’s condition render the patient unable to 
receive further treatment in the judgment  of the investigator  
• Suspected pregnancy  
• Serious noncompliance with the study protocol  
• Lost to follow -up 
• Patient withdraws consent  
• Investigator removes the patient from study  
• The Siteman Cancer Center decides to close the study  
 
Patients who prematurely discontinue treatment for any reason will be followed as 
indicated in the study calendar . 
 
5.[ADDRESS_1181012] ed via phone for follow -up assessments. 
 
 
6 DOSE DELAYS/DOSE MODIFICATIONS  
 
Participants will be monitored continuously for AEs while on study therapy. Participants will be 
instructed to notify their physician for any and all AEs. Dose modifications in this section for chemotherapy are meant as a general guidance. Modifications sh ould be applied by [CONTACT_1275]’s judgment. In case of an AE relationship assignment to chemotherapy alone, dose modifications for chemotherapy alone are allowed. In case of doubt, both chemotherapy and BMS -
[ADDRESS_1181013] of care rules for dose reduction should also be applied.  
 For an AE requiring dose modification, BMS -813160, chemotherapy, and/or nivolumab should be 
interrupted to allow recovery from the AE. Re -initiation of study treatment cannot occur until the 
AE decreases to ≤  Grade 1 or baseline assessment. In case of delayed recovery to ≤  Grade 1 or 
baseline from treatment -related AEs that result in a delay of treatment fo r > 28 days, the participant 
Protocol Version:  05/16/2022 – Amendment [ADDRESS_1181014] of the participant to 
receive additional therapy with BMS -813160 and/or other study treatments.  
 
6.1 Dose Modifications for BMS -813160 
 
Please refer to Section 5 for study drug administration guidelines.  
 
Dose Level  BMS -813160  
0 (starting)  300 mg  BID 
-1 150 mg BID 
-2 150 mg QD 
 
• New onset of QTcF intervals > 500 msec or prolongation > 50 msec over baseline, new  
onset QRS intervals > [ADDRESS_1181015]- degree heart block will require dose interruption 
and restarting at one dose level lower. Any  electrolyte abnormalities should be 
corrected and  ECG should be repeated with cardiology consultation if clinically 
indicated.  
• Grade 3 non- hematologic toxicity or Grade 4 non -hematologic toxicity attributed to  
BMS -813160 will require  immediate discontinua tion until recovery to baseline. BMS -
813160 will then be resumed at  one dose level reduction. 
• Any Grade 3 laboratory only abnormalities without clinical manifestations or electrolyte abnormalities that may be managed with supplementation can be managed 
with dose delay and do not automatically need dose modification. 
• Participants who hold BMS -[ADDRESS_1181016] of the 
cycle.  
• Participants who hold BMS -813160 for more than 7 days or for drug toxicity will hold  
treatment for the remainder of the cycle and start at a reduced dose for the next cycle.  
• Participants who hold BMS -813160 for more than 7 days due to events deemed 
unlikely or not related to BMS -813160 may resume BMS -813160 at the same dose 
level  after discussion with the PI  [INVESTIGATOR_849370]. Missed doses will be  skipped. 
• If chemotherapy or nivolumab is delayed due to toxicity attributable to chemotherapy 
or nivolumab alone or due to scheduling issues, participants can continue on BMS -
813160 alone. Participants who need a dose reduction for toxicity attributable to BMS -
813160 will continue on the reduced dose of BMS -813160 for t he remainder of the 
study.  
• If a participant needs more than 2 dose reductions of BMS -813160 for toxicity, the  
participant will be taken off BMS -813160 and nivolumab, but can continue 
chemotherapy if it is determined to be in the participant’s best interest as per the treating 
investigator.  
• If a participant is off BMS -813160 for more than 28 days, the participant will 
permanently  discontinue treatment and be taken off study, unless it is determined to  be 
in the  participant’s best interest as per the treating investigator.  
Protocol Version:  05/16/2022 – Amendment 7  Page 30 of 83  
6.2 Dose Modifications for Nivolumab  
 
No dose modifications allowed.  Doses can be delayed for side effects.  Nivolumab will be 
withheld for drug -related toxicities and severe or life- threatening AEs as per the table 
below. 
 
Nivolumab administration should be delayed for the following:  
• Grade 2 non -skin, drug -related AE, with the exception of fatigue  
• Grade [ADDRESS_1181017], ALT and/or Total Bilirubin abnormalities  
• Grade 3 skin, drug- related AE  
• Grade 3 drug -related laboratory abnormality, with the following exceptions:  
− Grade 3 lymphopenia or asymptomatic amylase or lipase does not require dose delay  
− Grade ≥  [ADDRESS_1181018], ALT, Total Bilirubin will require dose discontinuation 
• Any adverse event, laboratory abnormality, or intercurrent illness which, in the 
judgment of the investigator, warrants delaying the dose of study medication. 
 
Participants who require delay of nivolumab should be re -evaluated weekly or more 
frequently if clin ically indicated and resume nivolumab dosing when re -treatment criteria 
are met.  
 
Nivolumab treatment should be permanently discontinued for the following:  
• Any Grade 2 drug -related uveitis, eye pain or blurred vision that does not respond 
to topi[INVESTIGATOR_52201] y and does not improve to Grade 1 severity within the re -treatment 
period OR requires systemic treatment   
• Any Grade 3 non -skin, drug -related AE lasting > 7 days or recurs, with the 
following exceptions for laboratory abnormalities, drug -related uveitis, 
pneumonitis, bronchospasm, neurologic toxicity, hypersensitivity reactions, 
infusion reactions, and endocrinopathies:  
− Grade 3 drug- related uveitis, pneumonitis, bronchospasm , neurologic toxicity, 
hypersensitivity reaction, or infusion reaction of any duration requires 
discontinuation 
− Grade 3 drug- related endocrinopathies, adequately controlled with only 
physiologic hormone replacement do not require discontinuation. Adrenal insufficiency requires discontinuation regardless of control with hormone 
replacement.   
− Grade 3 drug- related laboratory abnormalities do not require treatment 
discontinuation except:  
♦ Grade 3 drug -related thrombocytopenia > 7 days or associated with 
bleeding requires discontinuation 
♦ Grade ≥ [ADDRESS_1181019], ALT or Total Bilirubin requires 
discontinuation 
♦ Concurrent AST or ALT > [ADDRESS_1181020] and total bilirubin > 2x ULN  
Protocol Version:  05/16/2022 – Amendment 7  Page 31 of 83 • Any Grade 4 drug -related adverse event or laboratory abnormality (including but 
not limited to creatinine, AST, ALT, or Total Bilirubin), except for the following 
events which do not require discontinuation:  
− Grade 4 neutropenia ≤  7 days  
− Grade 4 lymphopenia or leukopenia or asymptomatic amylase or lipase  
− Isolated Grade 4 electrolyte imbalances/abnormalities that are not associated  
with clinical sequelae and are corrected with supplementation/appropriate management within 72 hours of their onset  
− Grade 4 drug -related endocrinopathy adverse events, such as, hyper - or 
hypothyroidism, or glucose intolerance, which resolve or are adequat ely 
controlled with physiologic hormone replacement (corticosteroids, thyroid 
hormones) or glucose -controlling agents, respectively, may not require 
discontinuation after discussion with and approval from the BMS Medical 
Monitor. 
• Any event that leads to delay in dosing lasting > 4 weeks from the previous dose 
requires discontinuation, with the following exceptions:  
− Dosing delays to allow for prolonged steroid tapers to manage drug- related 
adverse events are allowed.  
− Dosing delays lasting > 6 weeks from the  previous dose that occur for non-
drug- related reasons may be allowed if approved by [CONTACT_513022] .  
 
Prior to re -initiating treatment in a participant with a dosing delay lasting >  [ADDRESS_1181021] be consulted. Tumor asse ssments should continue as per 
protocol even if dosing is delayed. Periodic study visits to assess safety and laboratory 
studies should also continue every 6 weeks or more frequently if clinically indicated during such dosing delays . 
 
6.3 Dose Modifications for Gemcitabine and Nab -Paclitaxel  
 
Dose Level  Gemcitabine  Nab-Paclitaxel  
0 (starting)  1000 mg/m2 125 mg/m2 
-1 800 mg/m2 100 mg/m2 
-2 600 mg/m2 75 mg/m2 
If additional dose 
reduction required  At PI’s discretion  
 
  
Protocol Version:  05/16/2022 – Amendment 7  Page 32 of 83  
Dose Modifications for Hematological Toxicity  
1. Doses held during a cycle (i.e. D8 or D15) will not be made up.  
a. If ANC < 500 with C1, re -check CBC within 7 days. If ANC < 500 for 7 days or longer, consult 
with PI [INVESTIGATOR_849371] (per Section 5.3.2)  
b. If platelets < 75,000 with C1, may be DLT. Consult with PI [INVESTIGATOR_849372] (per Section 5.3.2)  
2. Grade 3 -4 Febrile Neutropenia at any point in the cycle (defined as temperature > 101 ℉ with a neutrophil 
count of < 1000 cells/ml), hold dosing until fever resolution and ANC > 1500 and resume  at next lower 
dose level.  
3. Recurrent Grade 3 -4 Febrile Neutropenia at any point in the cycle 1 or 2, h old dosing until fever 
resolution and ANC > 1500 and resume at next lower dose level.  
4. Upon recovery of platelets ≥  75,000 and ANC ≥ 1000, dose reduce 1 level at next scheduled visit  
5. Upon recovery of platelets ≥  75,000 and ANC ≥ 1000, dose reduce 2 levels at next scheduled visit  
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  Cycle Day  ANC 
(cells/mm3)   Platelet count 
(cells/mm3)  Dosing 
Adjustment  
Day 1  < 1500  OR < 100,000  Delay doses until 
recovery  
Day 8  < 1000 a, b 
 OR < 75,000 a, b Withhold doses 1, 4 
Day 15  
if Day 8 doses were reduced or 
given without modification  < 1000 a, b 
 OR < 75,000 a, b Withhold doses 1, 4 
Day 15  
if Day 8 doses were withheld  ≥ 1000  OR ≥ 75,000  Treat with 1 dose 
level reduction from 
Day 1  
 
< 1000 a, b OR < 75,000 a, b Withhold doses 1, 5 
    
Protocol Version:  05/16/2022 – Amendment 7  Page 33 of 83 Dose Modifications for Other Treatment -Related Non -Hematological Toxicities  
Adverse Drug Reaction  Gemcitabine  Nab-Paclitaxel  
Peripheral neuropathy (Grade 2)  No dose reduction  Dose reduction allowed PI [INVESTIGATOR_849373]  
(Grade 3 or 4)   No dose reduction   Withhold until improves to ≤ grade 
1; resume at next lower dose level  
Cutaneous toxicity  
(Grade 2 or 3)  Reduce to next lower dose level; discontinue treatment if grade 2 or 
3 toxicity persists   
Gastrointestinal toxicity  
(Grade 3 mucositis or diarrhea)  Withhold until improves to ≤ grade 1; resume at next lower dose 
level  
Unexplained dyspnea or other 
evidence of severe pulmonary 
toxicity  Discontinue  No dose reduction  
Grade 3 or 4 hepatic toxicity  Dose Modification at PI [INVESTIGATOR_849374]. If 
attributed to Gemcitabine, 
and not recovered to G1 
after 4 weeks, permanently 
discontinue  Do not administer to patients with 
total bilirubin > 1.[ADDRESS_1181022] 
> [ADDRESS_1181023]  
Hemolytic -Uremic Syndrome  Discontinue  No dose reduction  
Capi[INVESTIGATOR_849375] 3 or 4 non -
hematological toxicity (except 
nausea or vomiting)  Withhold or reduce by [CONTACT_849395]  
 
[CONTACT_27891] 3 or 4 nausea and vomiting  If strongly attributed to chemotherapy, dos e reduction at PI’s 
discretion upon resolution to G1 or baseline  
 
6.4 Treatment Beyond Progression  
 
Pseudoprogression is a possibility for patients who experience actual clinical benefit from 
immunotherapi[INVESTIGATOR_849376] (see Section 12) . Therefore, 
participants will be permitted to continue treatment beyond initial RECIST v1.1 defined PD, assessed by [CONTACT_093], as long as they meet the following criteria: 
• Investigator -assessed clinical benefit  
• Tolerance of study t reatment  
• Stable performance status  
• Treatment beyond progression will not delay an imminent intervention to prevent serious  complications of disease progression (eg, CNS metastases)  
• Participant provides written informed consent prior to receiving additional  
treatment. All other elements of the main consent including description of 
reasonably foreseeable risks or  discomforts, or other alternative treatment options 
will still apply.  
 
A radiographic assessment/scan should be performed at the next scheduled scan  to 
determine  whether there has been a decrease in the tumor size or continued PD. The 
assessment of clinical  benefit should be balanced by [CONTACT_849396]:  05/16/2022 – Amendment 7  Page 34 of 83 study treatment.  If the investigator feels that the participant continues to achieve clinical 
benefit by [CONTACT_143897], the participant should remain on the trial and continue to 
recei ve monitoring according  to the study calendar . For the participants who continue study 
therapy beyond progression, further progression is defined as an additional 10% increase 
in tumor burden with a minimum 5 mm absolute increase from time  of initial PD. T his 
includes an increase in the sum of diameters of all target lesions and/ or the  diameters of 
new measurable lesions compared to the time of initial PD. Study treatment should  be 
discontinued permanently upon documentation of further progression. The tum or burden  
volume from time of initial progression should be used as the reference baseline for 
comparison with the post progression assessment.  
 
New lesions are considered measureable at the time of initial progression if the longest 
diameter  is at least 1 0 mm (except for pathological lymph nodes which must have a short 
axis of at least  15 mm). Any new lesion considered non- measureable at the time of initial 
progression may  become measureable and therefore included in the tumor burden if the 
longest diamete r increases  to at least 10 mm (except for pathological lymph nodes which 
must have a short axis of at least  15 mm). In situations where the relative increase in total 
tumor burden by 10% is solely due to inclusion of new lesions which become measurable, 
these new lesions must demonstrate an  absolute increase of at least [ADDRESS_1181024] be 
recorded on the toxicity tracking case report form (CRF) with the exception of:  
• Baseline adverse events, which shall be recorded on the medical history CRF  
• Adverse events related to off -study, non- protocol related therapy  
 Refer to the data submission schedule in Section 11 for instructions on the collection of AEs in the EDC.  
 Reporting requirements for Washington University study team m ay be found in Secti on 7.1.  
Reporting requirements for secondary site study teams participating in Washington University -
coordinated research may also be found in Section 7.2. 
 
7.1 Sponsor -Investigator Reporting Requirements  
 
7.1.1 Reporting to the Human Research Protection Office (HRPO) at 
Washington University  
 
Protocol Version:  05/16/2022 – Amendment [ADDRESS_1181025] be obtained prior to implementing the 
change.   
 
7.1.2 Reporting to the Quality Assurance and Safe ty Monitoring Committee 
(QASMC) at Washington University 
 
The Washington University Sponsor -Investigator (or designee) is required to notify 
the QASMC of any unanticipated problem s involving risks to participants or others  
occurring at WU or any BJH or SLCH institution that has been reported to and acknowledged by [CONTACT_9077].  (Unanticipated problems reported to HRPO and withdrawn during the review process need not be reported to QASMC.)  
 QASMC must be notified within 10 days  of receipt of IRB acknowledgment via 
email to [EMAIL_167]
.  Submissions to  QASMC must include the myIRB 
form and any supporting documentation sent with the form . 
 For events that occur at secondary sites, th e Washing ton University Sponsor -
Investigat or (or designee) is required to notify the QASMC within 10 days of 
Washington University notification via email to [EMAIL_167].  Submission to QASMC must include either the myIRB form and supporting documentation or (if  
not submitted to myIRB) the date of occurrence, description of the event, whether the event is described in the currently IRB approved materials, the event outcome, determination of relatedness, whether currently enrolled participants will be notified, and whether the informed consent document and/or any study procedures will be modified as a result of this event.  
 
7.1.3 Reporting to [COMPANY_016]  
 
All Serious Adverse Events (SAEs) that occur following the subject’s written consent to participate in the s tudy through [ADDRESS_1181026] be collected that relate to any later protocol -
specified procedure (eg, a follow -up skin biopsy).  
 Following the subject’s written consent to participate in the study, all SAEs, whether related or not related to study drug, are collected, including those thought to be associated with protocol -specified procedures. The investigator should report 
any SAE occurring after these aforementioned time periods, which is believed to 
be related to study drug or protocol -specified procedure.  
 
Protocol Version:  05/16/2022 – Amendment [ADDRESS_1181027] be 
reported to BMS within 24 hours \ [ADDRESS_1181028] be reported and submitted to BMS on a MedWatch SAE form.   
SAE Email Address:  [EMAIL_176]  
SAE Facsimile Number:  [PHONE_4485] -818-3804  
 
If only limited information is initially available, follow -up reports are required. 
(Note: Follow -up SAE reports should include the same investigator term(s) initially 
reported.)  
 If an ongoing SAE changes in its intensity or relationship to study drug o r if new 
information becomes available, a follow -up SAE report should be sent within 24 
hours \  1 Business Day to BMS using the same procedure used for transmitting the 
initial SAE report.   All SAEs should be followed to resolution or stabilization.  
 
[IP_ADDRESS] Reconciliation  
  The Sponsor will reconcile the clinical database SAE cases (case level only) 
transmitted to BMS Global Pharmacovigilance 
([EMAIL_555]). Frequency of reconciliation should be 
every 3 months and prior to the database lock or final data summary. BMS GPV&E will email, upon request from the Investigator, the GPV&E reconciliation report. Requests for reconciliation should be sent to 
[EMAIL_177]. The data elements listed on the GPV&E 
reconciliation report will be use d for case identification purposes. If the 
Investigator determines a case was not transmitted to BMS GPV&E, the 
case should be sent immediately to BMS.  
 
[IP_ADDRESS] Early Asset every 3 month AE reporting  
 
Adverse Events that are routinely collected according to GCP shall be 
submitted to BMS every three (3) months by [CONTACT_849397].   
 The Adverse Event information required to be sent to BMS is noted in an attached ‘Bristol -Myers Squibb Early Asset Investigator Sponsored 
Research (ISR) Import Pl an’ which describes the method of collection and 
submission to BMS via the mailbox: MG -RD-GPVE -
[EMAIL_12059]  
 When the file is submitted to BMS, it must be noted the file contains:  
Protocol Version:  05/16/2022 – Amendment 7  Page 37 of 83 • All Non -serious Adverse Events (only adverse events not previously 
submitted to BMS within the 3 months).  
 
7.1.[ADDRESS_1181029] of the study will comply with all FDA safety reporting requirements.  
PLEASE NOTE THAT REPORTING REQUIREMENTS FOR THE FDA 
DIFFER FROM REPORTING REQUIREMENTS FOR HRPO/QASMC.  It 
is the responsibility of the Washington University principal investigator [INVESTIGATOR_849377]:  
 
• Report any unexpected fatal or life- threatening suspected adverse reaction 
(refer to Appendix F for definitions) no later than 7 calendar days  after 
initial receipt of the information.   
• Report a suspected adverse reaction that is both serious and unexpected (S[LOCATION_003]R, refer to Appendix F ) no later than 15 calendar days  after it is 
determined that the information qualifies for reporting.  Report an adverse 
event (refer to Appendix F ) as a suspected adverse reaction only if there is 
evidence to suggest a causal relationship between the drug and the adverse 
event, such as:  
o A single occurrence of an event that is uncommon and known to be strongly associated with drug exposure  
o One or more occurrences of an event that is not commonly associated 
with drug exposure but is otherwise uncommon in the population 
exposed to the drug 
o An aggregate analysis of specific events observed in a clinical trial that 
indicates those events occur more frequently in the drug treatment 
group than in a concurrent or historical control group 
• Report any findings from epi[INVESTIGATOR_9037], pooled analysis of 
multiple studies, or clinical studies that suggest a significant risk in humans exposed to the drug no later than 15 calendar days  after it is determined 
that the information qualifies for reporting.  
• Report any findings from animal or in vitro te sting that suggest significant 
risk in humans exposed to the drug no later than 15 calendar days  after it 
is determined that the information qualifies for reporting.   
• Report any clinically important increase in the rate of a serious suspected 
adverse react ion of that listed in the protocol or IB within [ADDRESS_1181030] bring the signed 1571 and FDA Form  3500A to the Siteman 
Cancer Center Protocol Development team no later than 1 business day prior to the 
due date for reporting to the FDA.  
Protocol Version:  05/16/2022 – Amendment [ADDRESS_1181031] bear prominent identification of its contents (“IND 
Safety Report”) and must be transm itted to the review division in the Center for 
Drug Evaluation and Research (CDER) or in the Center for Biologics Evaluation 
and Research (CBER) that has responsibility for review of the IND.  Relevant follow -up information to an IND safety report must be submitted as soon as the 
information is available and must be identified as such (“Follow -up IND Safety 
Report”).  
 
7.1.5 Reporting to Secondary Sites  
 
The Washington University Sponsor -Investigator  (or designee) will notify the 
research team at each secondary si te of all unanticipated problems involving risks 
to participants or others  that have occurred at other sites within [ADDRESS_1181032] both at Washington 
University and at other secondary sites, if applicable.  Refer to section 16.0 
(Multicenter Management) for more information.  
 
7.2 Reporting Requirements for Secondary Sites  
 
The research team at each secondary site is required to promptly notify the Washington 
University Sponsor -Investigator and designee of all serious adverse events (as described in 
APPENDIX F and G ) within 1 working day of the occurrence of the event or noti fication 
of the secondary site’s PI [CONTACT_12581].  This notification may take place via email if there is not yet enough information for a formal written report using FDA Form 3500a (MedWatch ) form  and Washington University ’s Cover Sheet (APPENDIX H).    A formal 
written report must be sent to the Washington University Sponsor -Investigator and 
designee  within 4 calendar days  (for fatal or life -threatening suspected adverse reactions ) 
or 11 calendar days (for serious unexpected suspected adverse reaction s) of the 
occurrence of the event or notification of the secondary site’s PI [INVESTIGATOR_849378] a secondary site is responsible for following its site’s guidelines for 
reporting applicable events to its site’s IRB according to its own institutional guidelines.   
The research team at Washington University is responsible for reporting all applicable 
events to the FDA  and [COMPANY_016] as needed.  
 
Washington University pre -approval of all protocol exceptions must be obtained prior to 
implementing the change.  Local IRB approval must be obtained as per local guidelines.  
Washington University IRB approval is not required for protocol exceptions occurring at secondary sites.  
 
 
 
  
Protocol Version:  05/16/2022 – Amendment 7  Page 39 of 83 8 PHARMACEUTICAL INFORMATION 
 
8.1 BMS -813160 
 
8.1.1 BMS -813160 Description  
 
Molecular Formula: C 25H40N8O2 
Molecular Weight: 484.64 
 
8.1.2 Clinical Pharmacology  
 
Inhibition of the CCR2 receptor with BMS -813160 impedes the ability of MCP -1 
to bind to the  CCR2 receptor and internalize to activate subsequent signaling 
pathways within the cell. As this  internalization of MCP -1 is the main mechanism 
of MCP -1 clearance from the circulation,  inhibition of this association and 
internalization would lead to increases in MCP -1 in circulation. Therefore, if BMS -
813160 effectively binds to and inhi bits the CCR2 receptor, MCP -1 levels in  the 
plasma would increase.  
 
8.1.3 Pharmacokinetics and Drug Metabolism  
 
• The t½ of BMS -813160 in dose groups that had a well characterized terminal 
phase was approximately 12 to 18 hours, which may be amenable for QD 
dosing . 
• Renal excretion (%UR) of BMS -813160 generally increased and CLT/F 
generally decreased with increasing dose, suggesting a dose- related increase in 
the oral bioavailability of BMS -813160.  
• A total of 81.5% of the administered radiolabeled dose was recovered as [14C]: 
the majority in feces (58.7%) and the remaining amount in urine (22.8%).  
• BMS -813160 was the predominant drug -related component in the plasma, and 
BMS -939429 was a prominent metabolite, accounting for 53% and 30% of total 
[14C]. The parent drug, together with selected metabolites that were quantified 
with an exploratory LC -MS/MS assay, comprised approximately 87% of the 
circulating radioactivity.  
 
8.1.4 Supplier(s)  
 BMS -813160 will be supplied by [CONTACT_43899].  At the end of the study 
period, Br istol- Myers Squibb Company will not continue to supply study drug to 
subjects/investigators unless the Sponsor -Investigator chooses to extend their 
study. The investigator is responsible to ensure that the subject receives appropriate standard of care or o ther appropriate treatment in the independent medical 
judgement of the Investigator to treat the condition under study.  
 
8.1.5 Dosage Form and Preparation  
 
Protocol Version:  05/16/2022 – Amendment 7  Page 40 of 83 BMS -813160 is available in 150- mg strength capsules for oral administration.  
 
8.1.6 Storage  and Stability  
 
BMS -813160 capsules should be stored between 2°C and 25°C (35.6°F and 77°F) 
in a tightly closed container.  
 
8.1.7 Administration  
 
To be taken by [CONTACT_410142] a daily basis as described in Section 5.1. 
 
8.1.8 Special Handling Instructions  
 
None.  
 
8.2 Nivolumab (Opdivo)  
 
8.2.1 Nivolumab Description  
 
Nivolumab is a programmed death receptor -1 (PD -1) blocking antibody indicated 
for the treatment of patients with:  
• BRAF V600 wild -type unresectable or metastatic melanoma, as a single 
agent  
• BRAF V600 mutation positive unresectable or metastatic melanoma, as a 
single agent  
• Unresectable or metastatic melanoma, in combination with ipi[INVESTIGATOR_125]  
• Metastatic non -small cell lung cancer and progression on or after platinum -
based chemotherapy  
• Advanced renal cell carcinoma who have received prior anti -angiogenic 
therapy  
• Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation and post -transplantation 
brentuximab vedotin  
• Recurrent or metastatic squamous cell carcinoma of the head and neck wit h 
disease progression on or after a platinum -based therapy  
 
It is a human monoclonal antibody that blocks the interaction between PD -[ADDRESS_1181033] c an contribute 
to inhibition of active T -cell immune surveillance of tumors. Nivolumab is a human 
Protocol Version:  05/16/2022 – Amendment 7  Page 41 of 83 immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD -[ADDRESS_1181034] -
mediated i nhibition of the immune response, including the anti -tumor immune 
response. In syngeneic mouse tumor models, blocking PD -1 activity resulted in 
decreased tumor growth. 
 
8.2.3 Pharmacokinetics and Drug Metabolism  
 
The pharmacokinetics (PK) of nivolumab was studie d in patients over a dose range 
of 0.1 to 20 mg/kg administered as a single dose or as multiple doses of nivolumab 
every 2 or 3 weeks. Nivolumab clearance decreases over time, with a mean 
maximal reduction (% coefficient of variation [CV%]) from baseline v alues of 
approximately 24.5% (47.6%) resulting in a geometric mean steady state clearance (CLss) (CV%) of 8.2 mL/h (53.9%); the decrease in CLss is not considered clinically relevant. The geometric mean volume of distribution at steady state (Vss) (CV%) is  6.8 L (27.3%), and geometric mean elimination half -life is 25 days 
(77.5%).  Steady -state concentrations of nivolumab were reached by 12 weeks 
when administered at 3 mg/kg every 2 weeks, and systemic accumulation was 
approximately 3 -fold. The exposure to nivolumab increased dose  proportionally 
over the dose range of 0.1 to 10 mg/kg administered every 2 weeks.  
 
8.2.4 Supplier(s)  
 
Nivolumab will be supplied by [CONTACT_43899].  At the end of the study period, Bristol -Myers Squibb Company will not continue to supply study drug to 
subjects/investigators unless the Sponsor -Investigator chooses to extend their 
study. The investigator is responsible to ensure that the subject receives appropriate standard of care or other appropriate treatment in the independent me dical 
judgement of the Investigator to treat the condition under study.  
 
8.2.5 Dosage Form and Preparation  
 
Nivolumab is available as a 40 mg/4 mL (10 mg/mL) and 40 mg/4 mL (10 mg/mL) 
and 100 mg/10 mL (10 mg/mL) solution in a single -use vial.  Each kit will conta in 
1 40mg vial and 2 100mg vials. As Nivolumab is administered fixed dose at 480mg, 
each patient will be dispensed 2 kits per dose to achieve the 480mg target.  
 
• Withdraw the required volume of nivolumab and transfer into an 
intravenous container.  
• Dilute nivolumab with either 0.9% Sodium Chloride Injection, USP or 5% 
Dextrose Injection, USP, to prepare an infusion with a final concentration 
ranging from 1 mg/mL to 10 mg/mL.  
• Mix diluted solution by [CONTACT_5237]. Do not shake.  
• Discard partially used vials or empty vials of nivolumab. 
 
8.2.6 Storage and Stability  
Protocol Version:  05/16/2022 – Amendment [ADDRESS_1181035] does not contain a preservative.  
 
After preparation, store the nivolumab infusion either:  
• at room temperature for no more than 4 hours from the time of preparation. 
This includes room temperature storage of the infusion in the IV container 
and time for  administration of the infusion or  
• under refrigeration at 2°C to 8°C (36°F -46°F) for no more than [ADDRESS_1181036] from Light  
 
8.2.7 Administration  
 
Administer the infusion over 30 minutes through an intravenous line containing a 
sterile, nonpyrogenic, low protein binding in- line filter (pore size of 0.2 micrometer 
to 1.2 micrometer).  
 Do not coadminister other drugs through the same intravenous line.  
 Flush the intravenous line at end of infusion.  
 
8.3 Gemcitabine (Gemzar)  
 
8.3.1 Gemcitabine Description  
 
Gemcitabine is a nucleoside metabolic inhibitor that exhibits antitumor activity.  Gemcitabine HCl is 2’ -deoxy -2’,2’ -difluorocytidine monohydrochloride (β -
isomer).  The structural formula is as follows:  
 
 
The empi[INVESTIGATOR_849379] C
9H11F2N3O4·HCl.  It has a 
molecular weight of 299.66. 
 
8.3.2 Clinical Pharmacology  
 
Gemcitabine kills cells undergoing DNA synthesis and blocks  the progression of 
cells through the G1/S -phase boundary.  Gemcitabine is metabolized by [CONTACT_849398] (dFdCDP) and triphosphate (dFdCTP) nucleosides. 
Gemcitabine diphosphate inhibits ribonucleotide reductase, an enzyme responsible 

Protocol Version:  05/16/2022 – Amendment 7  Page 43 of 83 for catalyzing the reactions that generate deoxynucleoside triphosphates for DNA 
synthesis, resulting in reductions in deoxynucleotide concentrations, including 
dCTP. Gemcitabine triphosphate competes with dCTP for incorporation into DNA. 
The reduction in the  intracellular concentration of dCTP by [CONTACT_849399] (self-potentiation). After the gemcitabine nucleotide is incorporated into DNA, 
only one additional nucleotide is added to the growing DNA strands, which 
eventually results in the initiation of apoptotic cell death.  
 
8.3.3 Pharmacokinetics and Drug Metabolism  
 
Gemcitabine disposition was studied in 5 patients who received a single 1000 
mg/m
2/30 minute infusion of radiolabeled drug. Within one (1) week, 92% to 98% 
of the dose was recovered, almost entirely in the urine. Gemcitabine (<10%) and 
the inactive uracil metabolite, 2 ’-deoxy -2’,2’-difluorouridine (dFdU), accounted 
for 99% of the excreted dose. The metabolite dFdU is also found in plasma.   The active metabolite, gemcitabine triphosphate, can be extracted from peripheral blood mononuclear cells. The half -life of the terminal phase for gemcitabine 
triphosphate from mononuclear cells ranges from 1.7 to 19.4 hours.  
8.3.4 Supplier(s)  
 
Gemcitabine will be given as per routine care from commercial supply.  
 8.3.5 Dosage Form and Preparation  
 
Gemcitabine for injection, USP, is available in sterile single -use vials individually 
packaged in a carton containing: [ADDRESS_1181037] ored at controlled room temperature 20°C to 25°C and that allows 
for excursions between 15°C and 30°C. 
 
8.3.7 Administration  
 
Gemcitabine should be given as an intravenous infusion over the course of 30 
minutes.  
 
8.3.8 Special Handling Instructions  
 
No special handlin g instructions. 
Protocol Version:  05/16/2022 – Amendment 7  Page 44 of 83  
8.4 Nab-Paclitaxel (Abraxane)  
 
8.4.1 Nab-Paclitaxel Description  
 
Nab-paclitaxel is an albumin -bound form of paclitaxel with a mean particle size of 
approximately 130 nanometers.  The active agent is paclitaxel, a microtubule 
inhibitor.  The chemical  name [CONTACT_537534] 5β,20 -Epoxy -1,2α,4,7β,10β,13α -
hexahydroxytax -11-en-9-one 4,10- diacetate 2 -benzoate 13 -ester with (2 R,3S)-N-
benzoyl -3-phenylisoserine.  Paclitaxel has the following structural formula:  
 
 
Paclitaxel is a white to off -white crystallin e powder with the empi[INVESTIGATOR_62497] 
C47H51NO 14 and a molecular weight of 853.91.  It is highly lipophilic, insoluble in 
water, and melts at approximately 216 -217°C.  
 
8.4.2 Clinical Pharmacology  
 
Nab-paclitaxel is a microtubule inhibitor that promotes the assembly of 
microtubules from tubulin dimers and stabilizes microtubules by [CONTACT_374121].  This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions.  Paclitaxel induces abnormal arrays or “bundles” of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.  
 
8.4.3 Pharmacokinetics and Drug Metabolism  
 
Following intravenous administration of nab -paclitaxel , paclitaxel plasma 
concentrations declined in a biphasic manner, the initial rapid decline representing distribution to the peripheral c ompartment and the slower second phase 
representing drug eli mination. The terminal half -life was approximately 27  hours. 
 In vitro studies with human liver microsomes and tissue slices showed that paclitaxel was metabolized primarily to 6αhydroxypaclitaxel by [CONTACT_097]2C8; and to two minor metabolites, 3’ -p-hydroxypaclitaxel and 6α, 3’ -p-dihydroxypaclitaxel, 
by [CONTACT_097]3A4. In vitro , the metabolism of paclitaxel to 6α -hydroxypaclitaxel was 
inhibited by a number of agents (ketoconazole, verapamil, diazepam, quinidine, dexamethasone, cyclos porin, tenipos ide, etoposide, and vincristine), but the 

Protocol Version:  05/16/2022 – Amendment 7  Page 45 of 83 concentrations used exc eeded thos e found in vivo follow ing normal therapeutic 
doses. T estosterone, 17α -ethinyl estr adiol, retinoic acid, and querc etin, a sp ecific 
inhibitor of CYP2C8, als o inhibited the formation of 6α -hydroxypaclitaxel in vitro. 
The pharmacokinetics of paclitaxel may also be altered in v ivo as a result of 
interactions with c ompounds that are substrates, inducers, or inhibitors of CYP2C8 
and/or CYP3A4. 
 
8.4.4 Supplier(s)  
 
Nab-paclitaxel  will be given as per routine care from commercial  supply.  
 
8.4.5 Dosage Form and Preparation  
 
It is supplied as a white to yellow, sterile, lyophilized powder for reconstitution 
with 20mL of 0.9% sodium chloride injection, USP prior to intravenous infusion.  Each single use vial contains 100 mg of paclitaxel ( bound to human albumin) and 
approximately 900 mg of human albumin (containing sodium caprylate and sodium acetyltryptophanate).  Each milliliter of reconstituted suspension contains 5 mg paclitaxel.  
 
8.4.6 Storage and Stability  
 
Store the vials in original carto ns at 20°C to 25°C.  Retain the original package to 
protect from bright light. 
 
8.4.7 Administration  
 
Nab-paclitaxel  should be given as an intravenous infusion over the course of 30 to 
40 minutes.  
 
8.4.8 Special Handling Instructions  
 
No special handling instructions. 
 
 
9 CORRELATIVE STUDIES  
 
9.1 Tumor Biopsy 
 
9.1.1 Collection of Specimens  
 
Collection of tumor core biopsies at the following time points is required:  
• Pre-treatment  
• End of C2 
• End of treatment for patients who progress or otherwise do not go to surgery  
• Surgery for pati ents who do go to surgery  
Protocol Version:  05/16/2022 – Amendment 7  Page 46 of 83  
A total of three core biopsies (with a 22- gauge needle) will be taken at each time 
point from each patient.  
 Tumor Biopsy can be omitted, if deemed by [CONTACT_976] [INVESTIGATOR_315226], that it may 
incur immediate, excessive health risks to patients. This determination (rationale 
and discussion with PI [INVESTIGATOR_315226]) should be clearly documented in visit 
notes. 
 
9.1.2 Handling of Specimens  
 
Both cores are to be cut in half with the top portion placed in 10% formalin buffered 
in PB S and the bottom portion snap frozen in liquid nitrogen.  Follow the processing 
instructions in the lab manual. 
 
9.1.3 Shippi[INVESTIGATOR_849380], Monday through Thursday only, via FedEx to:  
[CONTACT_187860] DeNardo  
Washington University School of Medicine  
[ADDRESS_1181038]. Louis, MO [ZIP_CODE] 
 
9.2 Peripheral Blood  
 
9.2.1 Collection of Specimens  
 
Four  heparinized green -top tubes each containing 8 -10mL of blood will be 
collected at t he following time points:  
• Cycle 1 Day 1 before treatment begins  
• after 2 cycles of treatment +/ - 3 days of mandatory tumor biopsy  
• End of treatment for patients who progress or otherwise do not go to 
surgery  
• no more than 24 hours prior to time of surgery (if applicable)   
 
9.2.2 Handling of Specimens  
 
Mix all blood tubes and process promptly (within 1 hour) upon receipt.  Follow the 
processing instructions in the lab manual.  
 
9.2.3 Shippi[INVESTIGATOR_849381] -delivered to the following labs:  
[CONTACT_187860] DeNardo  
Protocol Version:  05/16/2022 – Amendment [ADDRESS_1181039]. Louis, MO [ZIP_CODE] 
 
  
Protocol Version:  05/16/2022 – Amendment 7  Page 48 of 83 10 STUDY CALENDAR  
Screening/b aseline evaluations are to be conducted within [ADDRESS_1181040] be done no 
more than 4 weeks prior to the start of the protocol therapy.  There is a +/ - 2-day window for D1, D8 , and D15 of treatment, all laboratory  
assessments, and +/ - 7-day window for radiographic assessments and research tumor biopsies.  All lab evaluations will be reviewed with 
regard to dosing timeframe on D1, D8, D15.  
 Screening  Pre-
Tx Each 28 -day cycle2 End 
of C2  End of 
C4 End of 
tx Surgery5 Follow -up9 
D1 D8 D15 
Informed consent  X          
Physical exam, ECOG PS  X  X X (D8 or D15)       
CBC plus differential13 X  X X X      
CMP14 X  X X X      
CA19 -[ADDRESS_1181041] or MRI  X     X4 X   X 
EKG  X  X        
Randomization3  X         
BMS -813160    Taken  daily6      
Nivolumab    X6        
Gemcitabine    X X X      
Nab-paclitaxel    X X X      
Research tumor biopsy   X15    X15  X7,15 X15  
Research blood draw    X8   X  X7 X12  
AE assessment   X--------------------------------------------------  X10   
Progression and survival           X 
1. Women of childbearing potential only 
2. Total of up to 4 cycles  
3. Part A patients only  
4. Patients who progress will discontinue treatment at this point, while patients who achieve SD, PR, or CR will receive 2 more cycles of treatment  
5. Patients whose disease is considered resectable will undergo resection and come off treatment  (with specimens collected as part of this study)  
6. To patients randomized to the experimental group in Part A and all patients in Part B  
7. For patients who progress or otherwise do not go to surgery 8. Before treatment C1D1 only 
9. Q3-4Mo after whipple/EOT tumor collection  for the first two years after sur gery or until progression, whichever happens first  
10.  For patient proceeding to surgery (i.e .Whipple) at end of study treatment, collect until date of surgery. For patients that do no undergo s urgery, collect for [ADDRESS_1181042], Plt, MCV, RDW, differential includes neutrophil, ly mphocyte, monocyte percentage and absolute counts  
Protocol Version:  05/16/2022 – Amendment [ADDRESS_1181043], and ALP  
15. Tumor Biopsy can be omitted, if deemed  by [CONTACT_976] [INVESTIGATOR_315226], that it may incur immediate, excessive health risks to patients. This determination 
(rationale and discussion with PI [INVESTIGATOR_315226]) should be clearly documented in visit notes.
Protocol Version:  05/16/2022 – Amendment 7  Page 50 of 83  
11 DATA SUBMISSION SCHEDULE  
 
Case report  forms with appropriate source documentation will be completed according to the 
schedule listed in this section.  
 
Case Report Form  Submission Schedule  
Original Consent Form  Prior to registration  
On-Study Form  Prior to starting treatment  
Treatment Form  Every cycle  
Toxicity Form  Continuous  
Treatment Summary Form  Completion of treatment  
Research Tissue Form  Pre-treatment, end of C2, EOT  / surgery  
Research Blood Form  C1D1, end of C2, surgery  
Follow Up Form  Every 3 -4 months after whipple/EOT tumor collection 
for the first two years after surgery and per physician’s 
discretion afterwards  
Tumor Measurement Form  Baseline, end of C2, end of C4  
MedWatch Form  See Section 7.[ADDRESS_1181044] a regular  review 
of data status at all secondary sites, with appropriate correcti ve action to be requested as needed.  
 
11.1 AE Reporting in the EDC  
 
All adverse events that occur beginning with start of treatment (minus exceptions defined in Section 7.0) must be captured in the Toxicity Form.  Baseline AEs should be captured on the Medical History Form.  
 Participant death due to disease progression should be reported on the Toxicity Form as grade 5 disease progression.  If death is due to an AE (e.g. cardiac disorders: cardiac arrest), report as a grade [ADDRESS_1181045] – Solid Tumors  
 
For the purposes of this study, patients should be re -evaluated for response every 8 weeks.  
In addition to a baseline scan, confirmatory scans should al so be obtained not less than 4 
weeks following initial documentation of objective response.  
 
Response and progression will be evaluated in this study using the new international 
criteria proposed by [CONTACT_459] (RECIST) 
Protocol Version:  05/16/2022 – Amendment 7  Page 51 of 83 guideline (version 1.1) [Eur J Ca 45:228- 247, 2009].  Changes in the largest diameter 
(unidimensional measurement) of the tumor lesions and the shortest diameter in the case 
of malignant lymph nodes are used in the RECIST criteria.  
 
12.2 Disease Parameters  
 
Measurable disease:  Measurable lesions are defined as those that can be accurately measured in at least one dimension (longest diameter to be recorded) as >[ADDRESS_1181046] 
x-ray, as >[ADDRESS_1181047] scan, or >[ADDRESS_1181048] be recorded in millimeters (or decimal fractions of centimeters).  
 
Malignant lymph nodes :  To be considered pathologically enlarged and measurable, a 
lymph node must be >[ADDRESS_1181049] scan (CT scan slice 
thickness recommended to be no greater than 5 mm).  At baseline and in follow -up, only 
the short axis will be measured and followed.  
 Non-measurable disease:   All other lesions (or sites of disease), including small lesions 
(longest diameter <10 mm or pathological lymph nodes with ≥10 to <15 mm short axis), are considered non- measurable disease.  Bone lesions, leptomeningeal disease, ascites, 
pleural/pericardi al effusions, lymphangitis cutis/pulmonitis, inflammatory breast disease, 
and abdominal masses (not followed by [CONTACT_462]), are considered as non- measurable.  
 Note:  Cystic lesions that meet the criteria for radiographically defined simple cysts should not be considered as malignant lesions (neither measurable nor non- measurable) since 
they are, by [CONTACT_108], simple cysts.  
 ‘Cystic lesions’ thought to represent cystic metastases can be considered as measurable lesions, if they meet the definition of measur ability described above. However, if non-
cystic lesions are present in the same patient, these are preferred for selection as target lesions.  Target lesions :  All measurable lesions up to a maximum of 2 lesions per organ and 5 
lesions in total, representa tive of all involved organs, should be identified as target lesions 
and recorded and measured at baseline.  Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, but in addition should be those that lend themselves to reproducible repeated measurements.  
It may be the case that, on occasion, the largest lesion does not lend itself to reproducible 
measurement in which circumstance the next largest lesion which can be measur ed 
reproducibly should be selected.  A sum of the diameters (longest for non -nodal lesions, 
short axis for nodal lesions) for all target lesions will be calculated and reported as the 
baseline sum diameters.  If lymph nodes are to be included in the sum, t hen only the short 
axis is added into the sum.  The baseline sum diameters will be used as reference to further 
characterize any objective tumor regression in the measurable dimension of the disease.  
 
Non-target lesions :  All other lesions (or sites of dis ease) including any measurable lesions 
over and above the 5 target lesions should be identified as non- target lesions and should 
Protocol Version:  05/16/2022 – Amendment 7  Page 52 of 83 also be recorded at baseline.  Measurements of these lesions are not required, but the 
presence, absence, or in rare cases uneq uivocal progression of each should be noted 
throughout follow -up.  
 
New lesions:  New lesions are considered measureable at the time of initial progression if 
the longest diameter is at least 10 mm (except for pathological lymph nodes which must 
have a shor t axis of at least 15 mm). Any new lesion considered non- measureable at the 
time of initial progression may become measureable and therefore included in the tumor 
burden if the longest diameter increases to at least 10 mm (except for pathological lymph nodes which must have a short axis of at least 15 mm). In situations where the relative increase in total tumor burden by 10% is solely due to inclusion of new lesions which 
become measurable, these new lesions must demonstrate an absolute increase of at leas t 5 
mm. 
 
12.3 Methods for Evaluation of Measurable Disease  
 
All measurements should be taken and recorded in metric notation using a ruler or calipers.  
All baseline evaluations should be performed as closely as possible to the beginning of treatment and never more than 4 weeks before the beginning of the treatment.  The same method of assessment and the same technique should be used to characterize each identified and reported lesion at baseline and during follow -up. Imaging -based 
evaluation is preferred to eva luation by [CONTACT_460](s) being 
followed cannot be imaged but are assessable by [CONTACT_461].  
 Clinical lesions:   Clinical lesions will only be considered measurable when they are 
superficial (e.g., skin nodules and palpable lym ph nodes) and ≥ 10 mm diameter as assessed 
using calipers (e.g., skin nodules).  In the case of skin lesions, documentation by [CONTACT_3977], including a ruler to estimate the size of the lesion, is recommended.  
 Chest x -ray:  Lesions on chest x -ray ar e acceptable as measurable lesions when they are 
clearly defined and surrounded by [CONTACT_6776].  However, CT is preferable.   Conventional CT and MRI:   This guideline has defined measurability of lesions on CT 
scan based on the assumption that CT slice thickness is [ADDRESS_1181050] 
slice thickness greater than 5 mm, the minimum size for a measurable lesion should be 
twice the slice thickness.  MRI is also acceptable in certain situations (e.g. for body scans).   
 Use of MRI remains a complex issue.  MRI has excellent contrast, spatial, and temporal 
resolution; however, there are many image acquisition variables involved in MRI, which 
greatly impact image quality, lesion conspi[INVESTIGATOR_3934], and measurement.  Furthermore, t he 
availability of MRI is variable globally.  As with CT, if an MRI is performed, the technical 
specifications of the scanning sequences used should be optimized for the evaluation of the type and site of disease.  Furthermore, as with CT, the modality use d at follow -up should 
be the same as was used at baseline and the lesions should be measured/assessed on the 
same pulse sequence.  It is beyond the scope of the RECIST guidelines to prescribe specific 
Protocol Version:  05/16/2022 – Amendment [ADDRESS_1181051]:  At present, the low dose or attenuation correction CT portion of a combined 
PET- CT is not always of optimal diagnostic CT quality for use with RECIST 
measurements.  However, if the site can document that the CT performed as part of a PET -
CT is of identical diagnostic quality to a diagnostic CT (with IV and oral contrast), then the CT portion of the PET -CT can be used for RECIST measurements and can be used 
interchangeably with conventional CT in accurately measuring cancer lesions over time.  
Note, however, that the PET portion of the CT introduces additional data which may bias 
an investigator if it is not routinely or serially performed.   
 Ultrasound:   Ultrasound is not useful in assessment of lesion size and should not be used 
as a method of measurement.  Ultrasound examinations cannot be reproduced in their 
entirety for independent review at a later date and, because they are operator dependent, it cannot be guaranteed that the same technique and measurements will be taken from one assessment to the next.   If new lesions are identified by [CONTACT_13192], confirmation by [CONTACT_12154].  If there is concern about radiation exposure at CT, MRI may be used instead of CT in selected instances.  
 Endoscopy, Laparoscopy:   The utilization of these techniques for objective tumor 
evaluation is not advised.  However, such techniques may be useful to confirm complete pathological response when biopsies are obtained or to determine relapse in trials where recurrence following complete respon se (CR) or surgical resection is an endpoint. 
 Tumor markers:   Tumor markers alone cannot be used to assess response.  If markers are 
initially above the upper normal limit, they must normalize for a patient to be considered in complete clinical response.  Specific guidelines for both CA -125 response (in recurrent 
ovarian cancer) and PSA response (in recurrent prostate cancer) have been published [JNCI 96:487- 488, 2004; J Clin Oncol 17, 3461- 3467, 1999; J Clin Oncol 26:1148- 1159, 2008].  
In addition, the Gy necologic Cancer Intergroup has developed CA -[ADDRESS_1181052] -line trials in 
ovarian cancer [JNCI 92:1534- 1535, 2000]. 
 Cytology, Histology:   These techniques can be used t o differentiate between partial 
responses (PR) and complete responses (CR) in rare cases (e.g., residual lesions in tumor 
types, such as germ cell tumors, where known residual benign tumors can remain).  
 
The cytological confirmation of the neoplastic origi n of any effusion that appears or 
worsens during treatment when the measurable tumor has met criteria for response or stable 
disease is mandatory to differentiate between response or stable disease (an effusion may 
be a side effect of the treatment) and pr ogressive disease.  
 
Protocol Version:  05/16/2022 – Amendment 7  Page 54 of 83 FDG -PET:   While FDG -PET response assessments need additional study, it is sometimes 
reasonable to incorporate the use of FDG -PET scanning to complement CT scanning in 
assessment of progression (particularly possible 'new' disease).  New  lesions on the basis 
of FDG -PET imaging can be identified according to the following algorithm:  
 
• Negative FDG -PET at baseline, with a positive FDG -PET at follow -up is a sign of 
PD based on a new lesion. 
• No FDG- PET at baseline and a positive FDG -PET at fo llow-up:  If the positive 
FDG -PET at follow -up corresponds to a new site of disease confirmed by [CONTACT_4654], this 
is PD.  If the positive FDG -PET at follow -up is not confirmed as a new site of 
disease on CT, additional follow -up CT scans are needed to determine if  there is 
truly progression occurring at that site (if so, the date of PD will be the date of the 
initial abnormal FDG -PET scan).  If the positive FDG -PET at follow -up 
corresponds to a pre -existing site of disease on CT that is not progressing on the 
basis  of the anatomic images, this is not PD.  
• FDG -PET may be used to upgrade a response to a CR in a manner similar to a 
biopsy in cases where a residual radiographic abnormality is thought to represent fibrosis or scarring.  The use of FDG -PET in this circumstance should be 
prospectively described in the protocol and supported by [CONTACT_4623] -specific medical 
literature for the indication.  However, it must be acknowledged that both approaches may lead to false positive CR due to limitations of FDG -PET and 
biopsy re solution/sensitivity.  
  
Note:  A ‘positive’ FDG -PET scan lesion means one which is FDG avid with an uptake 
greater than twice that of the surrounding tissue on the attenuation corrected image.  
 
12.4 Response Criteria  
 
12.4.1 Evaluation of Target Lesions  
 
Complete Response (CR):   Disappearance of all target lesions.  Any pathological 
lymph nodes (whether target or non- target) must have reduction in short axis to <10 
mm. 
 
Partial Response (PR):   At least a 30% decrease in the sum of the diameters of 
target lesions, taking as reference the baseline sum diameters.  
 
Progressive Disease (PD):   At least a 20% increase in the sum of the diameters of 
target lesions, taking as reference the smallest sum on study (this includes the 
baseline sum if that is the smallest on stud y).  In addition to the relative increase of 
20%, the sum must also demonstrate an absolute increase of at least 5 mm.  (Note:  
the appearance of one or more new lesions is also considered progressions).  
 
Stable Disease (SD):  Neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as reference the smallest sum diameters while on 
study.  
Protocol Version:  05/16/2022 – Amendment 7  Page 55 of 83  
12.4.2 Evaluation of Non -Target Lesions  
 
Complete Response (CR):   Disappearance of all non- target lesions and 
normalization of tumor marke r level.  All lymph nodes must be non- pathological 
in size (<10 mm short axis). 
 
Note:  If tumor markers are initially above the upper normal limit, they must 
normalize for a patient to be considered in complete clinical response.  
 Non-CR/Non -PD:  Persiste nce of one or more non- target lesion(s) and/or 
maintenance of tumor marker level above the normal limits.  
Progressive Disease (PD):   Appearance of one or more new lesions and/or 
unequivocal progression of existing non- target lesions.  Unequivocal progression 
should not normally trump target lesion status.  It must be representative of overall disease status change, not a single lesion i ncrease.     
 Although a clear progression of “non -target” lesions only is exceptional, the 
opi[INVESTIGATOR_36408], and the progression status should be confirmed at a later time by [CONTACT_463] (or Princ ipal Investigator).  
 
12.4.[ADDRESS_1181053] response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements re corded since the treatment started).  The 
patient's best response assignment will depend on the achievement of both 
measurement and confirmation criteria.  
    
For Patients with Measurable Disease (i.e., Target Disease)  
Target 
Lesions  Non-Target Lesions  New  
Lesions  Overall 
Response  Best Overall Response when 
Confirmation is Required*  
CR CR No CR >4 wks. Confirmation**  
CR Non-CR/Non -PD No PR 
>4 wks. Confirmation** CR Not evaluated  No PR 
PR Non-CR/Non -PD/not evaluated  No PR 
SD Non-CR/Non -PD/not evaluated  No SD Documented at least once >4 
wks. from baseline**  
PD Any Yes or No  PD 
no prior SD, PR or CR  Any PD***  Yes or No  PD 
Any Any Yes PD 
* See RECIST 1.1 manuscript for further details on what is evidence of a new lesion.  
** Only for non- randomized trials with response as primary endpoint.  
*** In exceptional circumstances, unequivocal progression in non -target lesions may be accepted as disease progression.  
Protocol Version:  05/16/2022 – Amendment 7  Page 56 of 83 Note:  Patients with a global deterioration of health status requiring discontin uation of treatment without objective evidence 
of disease progression at that time should be reported as “symptomatic deterioration.”  Every effort should be made to 
document the objective progression even after discontinuation of treatment.  
 
                                      For Patients with Non -Measurable Disease (i.e., Non -Target Disease)  
Non-Target Lesions  New Lesions  Overall Response  
CR No CR 
Non-CR/non -PD No Non-CR/non -PD* 
Not all evaluated  No not evaluated  
Unequivocal PD  Yes or No PD 
Any Yes PD 
*  ‘Non -CR/non -PD’ is preferred over ‘stable disease’ for non -target disease since SD is 
increasingly used as an endpoint for assessment of efficacy in some trials so to assign this 
category when no lesions can be measured is not advised  
  
12.4.4 Duration of Response  
 
Duration of overall response:   The duration of overall response is measured from 
the time measurement criteria are met for CR or PR (whichever is first recorded) 
until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive d isease the smallest measurements recorded 
since the treatment started).  
 The duration of overall CR is measured from the time measurement criteria are first met for CR until the first date that progressive disease is objectively documented.   
 Duration of s table disease:   Stable disease is measured from the start of the 
treatment until the criteria for progression are met, taking as reference the smallest measurements recorded since the treatment started, including the baseline measurements.  
 
12.4.[ADDRESS_1181054] udy’s completion.  Simultaneous review of the patients’ files 
and radiological images is the best approach.  
  
[ADDRESS_1181055]  (DSM B) will be specifically convened for this 
Protocol Version:  05/16/2022 – Amendment [ADDRESS_1181056]. Louis Children’s Hospi[INVESTIGATOR_307].  Like investigators, DSM B members are 
subject to the Washington University School of Medicine policies regarding standards of conduct. Individuals invited to serve on the DSM B will disclose any potential conflicts of interest to the 
trial principal investigator [INVESTIGATOR_1238]/or appropriate university officials, in accordance with institution policies. Potential conflicts that develop during a trial or a member’s tenure on a DSMC must also be disclosed.  
 Until such a time as the first secondary site enrolls its first patient, a semi- annual DSM report to 
be prepared by [CONTACT_396838]  (QASMC) semi -annually beginning six months after study activation at Washington 
University (if at least one patient has been enrolled) or one year after study activation (if no patients have been enrolled at the six -month mark). 
 The DSM report will be pr epared by [CONTACT_430965] , 
will be reviewed by [CONTACT_9288] B, and will be submitted to the Quality Assurance and Safety 
Monitoring Committee (QASMC).  The DSMB must meet at least every si x months beginning six 
months a fter enrollment of the first patient at a secondary site  and no more than one month prior 
to the due date of the DSM report to QASMC.  This report will include:  
• HRPO protocol number, protocol title, Principal Investigator [CONTACT_2300], data coordinator name, regulatory coordinator name, and statistician  
• Date of initial HRPO approval, date of most recent consent HRPO approval/revision, date of HRPO expi[INVESTIGATOR_1516], date of most recent QA audit, study status, and phase of study  
• History of study including summary of s ubstantive amendments; summary of accrual 
suspensions including start/stop dates and reason; and summary of protocol exceptions, error, or breach of confidentiality including start/stop dates and reason  
• Study -wide target accrual and study -wide actual accru al including numbers from 
participating sites  
• Protocol activation date at each participating site  
• Average rate of accrual observed in year 1, year 2, and subsequent years at each participating site  
• Expected accrual end date, accrual by [CONTACT_3725], and accrual by  [CONTACT_9084]  
• Objectives of protocol with supporting data and list the number of participants who 
have met each objective  
• Measures of efficacy  
• Early stoppi[INVESTIGATOR_195574]  
• Summary of toxicities at all participating sites and separated by [CONTACT_849400] -limiting toxicities indicated  
• Abstract submissions/publications  
• Summary of any recent literature that may affect the safety or ethics of the study  
 
Further DSMC responsibilities are described in the DSM B charter.  
 
Protocol Version:  05/16/2022 – Amendment 7  Page 58 of 83 The study principal investigator [INVESTIGATOR_1238] c oordinator will monitor for all serious and non- serious 
adverse events  on an ongoing basis. Once the principal investigat[INVESTIGATOR_1660] [INVESTIGATOR_1660] c oordinator becomes aware 
of an advers e event, the AE will be reported to the HRPO and QASMC according to institutional 
guidelines  (please refer to Section 7.0) . 
 
Refer to the Washington University Quality Assurance and Data Safety Monitoring Committee Policies and Procedures for full details on the responsibilities of the DSMC at https://siteman.wustl.edu/research/clinical- research -resources/protocol -office -prmcqasmc/
. 
  
14 AUDITING  
 
As coordinating center of this trial, Washington University (via the Quality Assurance and Safety Monitoring Committee (QASMC) will monitor each participating site to ensure that all protocol requirements are being met; that applicable federal regulations are being followed; and that best practices for patient safety and data collection are being followed per protocol.   Participating sites 
will be asked to send copi[INVESTIGATOR_205143] , including source documentation.  The audit 
notification will be sent to the Washington University Research Patient Coordinator, who will obtain the audit materials from the participating institution.  
 Notification of an upcoming audit will be sent to the research team one month ahead of the audit. Once accrual numbers are confirmed, and approximately [ADDRESS_1181057] of the cases selected for review (up to 10 for each site) will be sent to the r esearch team. However, if 
during the audit the need arises to review cases not initially selected, the research team will be asked to provide the additional charts within two working days.  
 Items to be evaluated include:  
• Subject screening and enrollment  
• Reporting of adverse events  
• Maintenance of HIPAA compliance  
• Completeness of regulatory documentation  
• Completeness of participant documentation  
• Acquisition of informed consent  
• IRB documentation  
• Issues of protocol adherence  
 Additional details regarding the a uditing policies and procedures can be found at 
https://siteman.wustl.edu/wp -content/uploads/2015/10/QASMC -Policies -and-Procedures -
03.31.2015.pdf   
  
15 STATISTICAL CONSIDERATIONS  
 
15.1 Part A  
 
Protocol Version:  05/16/2022 – Amendment [ADDRESS_1181058], including frequency, type, and severity of adverse events. Based on the treatment 
plan (Section 5.0) , 16 patients  are randomized to 1:[ADDRESS_1181059] been 
enrolled and treated on the control arm, subsequent patients are enrolled only into the experimental arm.  Up to 18 patients will be enrolled on experimental arm to determine an 
MTD.  Due to small sample sizes and dose heterogeneity, no statistical tests of hypotheses 
are planned  specifically for this part of the study, but patients who receive MTD will be 
included in Part B for final analyses including ORR, PFS, OS and exploratory studies.   
 
15.2 Part B  
 
Part B  will be conducted subsequently to determine if there is a sufficiently high objective 
response rate (ORR) to warrant further studies.  
 
15.2.1 Sample size calculat ion 
 
The primary endpoint is ORR and the secondary endpoints include PFS and OS. 
The sample size calculation is based on the primary endpoint only. The objective response rate (ORR) of Gem/Abraxane in the MPACT study was 23%
31 and the 
disease control rate (DCR) was 48%. . There is interest in pursuing future studies if 
the DCR  is greater than 75%. A Simon optimal [ADDRESS_1181060] the null 
hypothesis that the true disease control  rate (DCR)  is less than or equal to 48% 
versus the alternative hypothesis that it exceeds 48 % at the type I error rate of 5%. 
In the first stage, [ADDRESS_1181061] 80% power to reject the null 
hypothesis when the true DCR  is 75%.    
 
The patients treated at the MTD in part A will be included in this expansion cohort.  
 
15.2.2 Stoppi[INVESTIGATOR_849382] 5 or fewer DCRs are observed out of these 9 patients, the study will be stopped. 
Otherwise, an additional 19 patients will be enrolled in the second stage. If 18 or 
more DCRs  are observed out of these 28 patients, we would conclude that 
preliminary evidence for efficacy exists.  
 
15.3 Statistical analysis  
 
Descriptive statistics will be used to summarize demographic and clinical characteristics , 
as well as  the trial results, i.e., statistics for continuous variables may include means, 
medians, ranges and appropriate measures of variability. Qualitative variables will be summarized by [CONTACT_33335] . All data will be evalua ted as observed, and no 
imputation method for missing values will be used.   The primary endpoint ORR and toxicity rates, and associated 95% confidence intervals, will be calculated assuming a binomial distribution of the number of subjects responding or e xperiencing toxicity. Due 
Protocol Version:  05/16/2022 – Amendment [ADDRESS_1181062] 
follow -up. For exploratory endpoints, investigations will use Wilcoxon signed- tests and 
paired t -tests to compare the difference of continuous variables before and after treat ment, 
and Fisher’s exact tests to compare binary response.  
  
16 MULTICENTER REGULATORY REQUIREMENTS  
 
Washington University requires that each participating site sends  its informed consent document 
to be reviewed and approved by [CONTACT_849401]  (or designee ) 
prior to IRB/IEC submission.     Site activation is defined as when the secondary site has received official written documentation from the coordinating center that the site has been approved to begin enrollment.  At a minim um, 
each participating institution must have the following documents on file at Washington University 
prior to study activation : 
• Documentation of IRB approval  of the study  in the form of a letter or other official 
document from the participating institutio n’s IRB.   This documentation must show which 
version of the protocol was approved by [CONTACT_1201].  
• Documentation of IRB approval of an informed consent form . The consent must include a 
statement that data will be shared with Washington University, including the  Quality 
Assurance and Safety Monitor ing Committee (QASMC), the DSMC  (if applicable) , and 
the Washington University study team.  
• Documentation of FWA, signed FDA Form 1572 (if applicable) , and the CVs of all 
participating investigators.  
• Protocol signature [CONTACT_144904] [CONTACT_144903].  
 The coordinating center Principal Investigator  (or designee)  is responsible for disseminating to the 
participating sites all study updates, amendments, reportable adverse events , etc.  Protocol /consent  
modifications and IB updates will be forwarded electronically to the secondary sites within 4 
weeks of obtaining Washington University IRB  approval.  Activated s econdary sites are expected 
to submit protocol /consent/IB  modifications to the ir local IRBs within 4 weeks of receipt  unless 
otherwise noted.  Upon the secondary sites obtaining local IRB approval, documentation of such shall be sent to the Washington University study team  within 2 weeks of receipt of approval.  
 Documentation of participating sites’ IRB approval of annual continuing reviews, protocol amendments or revisions, all SAE reports, and all protocol violations/deviations/exceptions must be kept on file at Washington University.  
Protocol Version:  05/16/2022 – Amendment [ADDRESS_1181063] participate in a regular conference call to update and inform regarding the progress of the trial.   
Protocol Version:  05/16/2022 – Amendment 7  Page 62 of 83 17 REFERENCES  
 
1 Siegel, R. L., Miller, K. D. & Jemal, A. Cancer Statistics, 2017. CA Cancer J Clin  67, 7- 30, 
doi:10.3322/caac.[ZIP_CODE] (2017). 
2 Teague, A., Lim, K. H. & Wang -Gillam, A. Advanced pancreatic adenocarcinoma: a review 
of current treatment strategies and developi[INVESTIGATOR_325473]. Ther Adv Med Oncol  7, 68- 84, 
doi:10.1177/1758834014564775 (2015).  
3 Royal, R. E . et al.  Phase 2 trial of single agent Ipi[INVESTIGATOR_125] (anti- CTLA -4) for locally 
advanced or metastatic pancreatic adenocarcinoma. Journal of immunotherapy  33, 828- 833, 
doi:10.1097/CJI.0b013e3181eec14c (2010).  
4 Feig, C.  et al.  The pancreas cancer microenvironm ent. Clin Cancer Res  18, 4266- 4276, 
doi:10.1158/1078- 0432.CCR -11-3114 (2012). 
5 Mitchem, J. B. et al.  Targeting Tumor -Infiltrating Macrophages Decreases Tumor -Initiating 
Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses. Cancer Res, doi:10.1158/0008- 5472.CAN -12-2731 (2013). 
6 Goedegebuure, P. et al.  Myeloid -derived suppressor cells: general characteristics and 
relevance to clinical management of pancreatic cancer. Curr Cancer Drug Targets  11, 734-
751 (2011).  
7 Bayne, L. J. et al.  Tumor-derived granulocyte -macrophage colony -stimulating factor 
regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer cell  21, 
822-835, doi:10.1016/j.ccr.2012.04.025 (2012).  
8 Goedegebuure, P. et al.  Myeloid -derived suppressor cells:  general characteristics and 
relevance to clinical management of pancreatic cancer. Curr Cancer Drug Targets  11, 734-
751 (2011).  
9 Tan, M. C. et al.  Disruption of CCR5- dependent homing of regulatory T cells inhibits tumor 
growth in a murine model of pancre atic cancer. J Immunol  182, 1746- 1755 (2009).  
10 Nywening, T. M. et al.  Targeting tumour -associated macrophages with CCR2 inhibition in 
combination with FOLFIRINOX in patients with borderline resectable and locally advanced 
pancreatic cancer: a single- centre, open -label, dose -finding, non- randomised, phase 1b trial. 
Lancet Oncol  17, 651- 662, doi:10.1016/S1470- 2045(16)[ZIP_CODE]- 4 (2016).  
[ADDRESS_1181064], D. E. et al.  Inflammatory monocyte mobilization decreases patient survival in 
pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin Cancer Res  19, 3404- 3415, 
doi:10.1158/1078- 0432.CCR -13-0525 (2013). 
12 Mitchem, J. B. et al.  Targeting tumor -infiltrating mac rophages decreases tumor -initiating 
cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res  
73, 1128- 1141, doi:10.1158/0008- 5472.CAN -12-2731 (2013).  
13 Loos, M. et al.  Expression of the costimulatory molecule B7 -H3 is associa ted with prolonged 
survival in human pancreatic cancer. BMC cancer  9, 463, doi:10.1186/1471 -2407- 9-463 
(2009).  
14 Porembka, M. R. et al.  Pancreatic adenocarcinoma induces bone marrow mobilization of 
myeloid -derived suppressor cells which promote primary tumor growth. Cancer 
immunology, immunotherapy : CII , doi:10.1007/s00262- 011-1178- 0 (2012). 
[ADDRESS_1181065] cancer cell 
extravasation, establishment and growth. PLoS One  4, e6562, 
doi:10.1371/journal.pone.0006562 (2009).  
Protocol Version:  05/16/2022 – Amendment 7  Page 63 of 83 16 Joyce, J. A. & Pollard, J. W. Microenvironmental regulation of metastasis. Nat Rev Cancer  9, 
239-252, doi:nrc2618 [pii]  
10.1038/nrc2618 (2009).  
17 Gabrilovich, D. I., Ostrand- Rosenberg, S. & Bronte, V. Coordinated regulation of  myeloid 
cells by [CONTACT_397344]. Nature reviews. Immunology  12, 253- 268, doi:10.1038/nri3175 (2012). 
[ADDRESS_1181066] cancer survival and functionally 
regulates response to chemotherapy. Cancer Discov  1, 54- 67, doi:10.1158/2159- 8274.CD -
10-0028 (2011).  
19 Qian, B. Z. & Pollard, J. W. Macrophage diversity enhances tumor progression and 
metastasis. Cell  141, 39- 51, doi:S0092- 8674(10)[ZIP_CODE]- 4 [pii]  
10.1016/j.cell.2010.03.014 (2010).  
20 Coussens, L. M. & Pollard, J. W. Leukocytes in Mammary Development and Cancer. Cold Spring Harb Perspect Biol , doi: cshperspect.a003285 [pii]  
10.1101/cshperspect.a003285 (2010).  
21 Kurahara, H. et al.  Significance of M2 -polarized tumor -associated macrophage in pancreatic 
cancer. The Journal of surgical research 167, e211- 219, doi:10.1016/j.jss.2009.05.026 
(2011).  
22 Kurahara, H. et al.  Clinical Significance of Folate Receptor beta- expressing Tumor -
associated Macrophages in Pancreatic Cancer. Annals of surgical oncology , 
doi:10.1245/s10434- 012-2263- 0 (2012).  
[ADDRESS_1181067], D. E. et al.  Inflammatory Monocyte Mobilization Decreases Patient Survival in 
Pancreatic Cancer: a Role for Targeting the CCL2/CCR2 Axis. Clin Cancer Res , 
doi:10.1158/1078- 0432.CCR -13-0525 (2013). 
[ADDRESS_1181068]- tumour 
metastasis. Nature  475, 222- 225, doi:nature10138 [pii]  
10.1038/nature10138.  
25 Zhao, L. et al.  Recruitment of a myeloid cell subset (CD11b/Gr1(mid) )via CCL2/CCR2 
promotes thedevelopment of colorectal cancer liver metastasis. Hepatology , 
doi:10.1002/hep.[ZIP_CODE] (2012). 
26 Hassan, R. & Ho, M. Mesothelin targeted cancer immunotherapy. Eur J Cancer  44, 46- 53, 
doi:10.1016/j.ejca.2007.08.028 (2008).  
27 Leao, I. C., Ganesan, P., Armstrong, T. D. & Jaff ee, E. M. Effective depletion of regulatory 
T cells allows the recruitment of mesothelin -specific CD8 T cells to the antitumor immune 
response against a mesothelin- expressing mouse pancreatic adenocarcinoma. Clinical and 
translational science  1, 228- 239, doi:10.1111/j.1752- 8062.2008.[ZIP_CODE].x (2008). 
28 Tang, C. K., Katsara, M. & Apostolopoulos, V. Strategies used for MUC1 immunotherapy: human clinical studies. Expert review of vaccines  7, 963- 975, doi:10.1586/14760584.7.7.963 
(2008).  
29 Huang, E. H. & Kaufma n, H. L. CEA -based vaccines. Expert review of vaccines  1, 49- 63, 
doi:10.1586/14760584.1.1.49 (2002).  
[ADDRESS_1181069], high -resolution analysis of the 
human naive and memory Th cell repertoire. J Immunol  190, 3967- 3976, 
doi:10.4049/jimmunol.1202221 (2013).  
31 Von Hoff, D. D. et al.  Increased survival in pancreatic cancer with nab -paclitaxel plus 
gemcitabine. N Engl J Med  369, 1691- 1703, doi:10.1056/NEJMoa1304369 (2013).  
Protocol Version:  05/16/2022 – Amendment 7  Page 64 of 83 32 Lacy, J.  et al.  Interim results o f a multicenter phase II trial of nab -paclitaxel (nab -P) plus 
gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC). Journal 
of Clinical Oncology  35, 358- 358, doi:10.1200/JCO.2017.35.4_suppl.358 (2017). 
 
We would like to thank the Alvin J. Siteman Cancer Center at Washington University School of Medicine and Barnes -Jewish Hospi[INVESTIGATOR_195577]. Louis, Missouri, for the use of the Clinical Trials 
Core which provided protocol development services . The Siteman Cancer Center is supported in 
part by [CONTACT_195605] #P30 CA91842.      
Protocol Version:  05/16/2022 – Amendment 7  Page 65 of 83 APPENDIX A: ECOG Performance Status Scale 
 
 
Grade  
  
Description  
0 Normal activity.  Fully active, able to carry on all pre -disease 
performance without restriction.  
1 Symptoms, but ambulatory.  Restricted in physically strenuous 
activity, but ambulatory and able to carry out work of a light or sedentary nature (e.g., light housework, office work). 
2 In bed <50% of the time.  Ambulatory and capable of all self -care, but 
unable to carry out any work activities.  Up and about more than 50% of waking hours.  
3  
In bed >50% of the time.  Capable of only limited self -care, confined 
to bed or chair more than 50% of waking hours.  
 
4 100% bedridden.  Completely disabled.  Cannot carry on any self -care.  
Totally confined to bed or chair.  
5  
Dead.  
 
   
Protocol Version:  05/16/2022 – Amendment 7  Page 66 of 83 APPENDIX B: PATIENT’S MEDICATION DIARY  
 
Today’s Date:      Agent:  BMS- 813160  Cycle:     Pt #: ________  
 
INSTRUCTIONS TO THE PATIENT:  
1. Complete one form for each month.  Take _____mg ( ___capsules) of BMS813160 ________ daily.  
2. Record the date, the number of capsules taken, and when you took them.  
3. If you forget to take your dose at the right time, you should make up for the missed BMS -[ADDRESS_1181070] the 
time if you should vomit.  
5. Please return the forms to your physician or your study coordinator when you go to your next appointment.  
Please bring your unused study medications and/or empty bottles with you to each clinic visit so that a pi[INVESTIGATOR_205954].  
Day Date  What time was dose taken?  Comm ents 
AM dose  PM dose  
1     
2     
3     
4     
5     
6     
7     
8     
9     
10     
11     
12     
13     
14     
15     
16     
17     
18     
19     
20     
21     
22     
23     
24     
25     
26     
27     
28     
Protocol Version:  05/16/2022 – Amendment 7  Page 67 of 83 APPENDIX C: CYP3A4 and P -GP Guidance  
 
The lists below are not meant to be all inclusive.  Please consult individual drug labels for further information.  Additional information is also available at: 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractio
nsLabeling/ucm093664.htm  
 
Please note th ese are not exhaustive list s. Only intravenous and oral therapy for strong 
CYP3A4 inhibitors such as ketoconazole are contraindicated. Topi[INVESTIGATOR_849383]3A4 
inhibitors is allowed.   
 
CYP Enzymes  Strong Inhibitors  Moderate Inhibitors  Weak Inhibitors  
CYP3A  Boceprevir, 
clarithromycin, 
conivaptan, grapefruit 
juice, indinavir, 
itraconazole, ketoconazole, lopi[INVESTIGATOR_054]/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, 
voriconazole  Amprenavir, 
aprepi[INVESTIGATOR_053], 
atazanavir, 
ciprofloxacin, 
darunavir/ritonavir, diltiazem, erythromyci n, 
fluconazole, fosamprenavir, grapefruit juice, imatinib, verapamil Alprazolam, 
amiodarone, 
amlodipi[INVESTIGATOR_050], 
atorvastatin, 
bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, nilotinib, oral contraceptive s, 
ranitidine, ranolazine, tipranavir/ritonavir, 
zileuton  
 
CYP Enzymes  Strong Inducers  Moderate Inducers  Weak Inducers  
CYP3A  Avasimibe, 
carbamazepi[INVESTIGATOR_050], phenytoin, rifampin, St. John’s wort  Bosentan, efavirenz, 
etravirine, modafinil, nafcillin  Amprenavir, 
aprepi[INVESTIGATOR_053], armodafinil, Echinacea, pi[INVESTIGATOR_051], prednisone, 
rufinamide  
 
Transporter  Inhibitors  
P-gp Amiodarone, carvedilol, clarithromycin, dronedarone, itraconazole, 
lapatinib, lopi[INVESTIGATOR_14475], propafenone, quinidine, ranolazine, ritonavir, sa quinavir and ritonavir, telaprevir, tipranavir and ritonavir, 
verapamil  
  
Protocol Version:  05/16/2022 – Amendment 7  Page 68 of 83 APPENDIX D: MATE Substrates Guidance  
 
The list below is not meant to be all- inclusive.  Please consult individual drug labels for further 
information.  
Transporter  Substrates  
MATE  Metformin, cisplatin, oxaliplatin, ganciclovir, acyclovir, procainamide, 
captopril, quinine  
 
  
Protocol Version:  05/16/2022 – Amendment 7  Page 69 of 83 APPENDIX E: Nivolumab Management Algorithms  
 
These general guidelines constitute guidance to the Investigator and may be supplemented by  
[CONTACT_849402] . The guidance applies to all  immuno -oncology agents 
and regimens.  
 
A general principle is that differential diagnoses should be diligently evaluated according to standard medical practice. Non- inflammatory etiologies should be considered and appropriately  
treated.  
 Corticosteroids are a primary therapy for immuno -oncology drug -related adverse events. The oral  
equivalent of the recommended IV doses may be considered for ambulatory patients with low -
grade  toxicity. The lower bioavailability  of oral corticosteroids should be taken into account when 
switching to the equivalent dose of oral corticosteroids.  Consultation with a medical or surgical specialist, especially prior to an invasive diagnostic or  
therapeutic procedure, is recommended.  
 The frequency and severity of the related adverse events covered by [CONTACT_849403]- oncology agent or regimen being used. 
  
Protocol Version:  05/16/2022 – Amendment 7  Page 70 of 83  

Protocol Version:  05/16/2022 – Amendment 7  Page 71 of 83  

Protocol Version:  05/16/2022 – Amendment 7  Page 72 of 83  

Protocol Version:  05/16/2022 – Amendment 7  Page 73 of 83  

Protocol Version:  05/16/2022 – Amendment 7  Page 74 of 83  

Protocol Version:  05/16/2022 – Amendment 7  Page 75 of 83  

Protocol Version:  05/16/2022 – Amendment 7  Page 76 of 83  

Protocol Version:  05/16/2022 – Amendment 7  Page 77 of 83 APPENDIX F: Definitions for Adverse Event Reporting  
 
A. Adverse Events  (AEs)  
 
As defined in 21 CFR 312.32:  
 
Definition:  any untoward medical occurrence associated with the use of a drug in humans, 
whether or not considered drug- related . 
 
Grading:  the descriptions and grading scales found in the revised NCI Common 
Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be utilized for all 
toxicity reporting .  A copy of the CTCAE version 5.0 can be downloaded from the CTEP 
website.  
 Attribu tion (relatedness), Expectedness, and Seriousness:  the definitions for the terms 
listed that should be used are those provided by [CONTACT_9092]’ Office for Human Research Protections (OHRP).  A copy of this guidance can be found on OHRP’s website:  
http://www.hhs.gov/ohrp/policy/advevntguid.html
 
 
B. Suspected Adverse Reaction (SAR)  
 As defined in 21 CFR 312.32:  
 Definition:  any adverse event for which there is a reasonable possibility that the drug 
caused the adverse event.  “Reasonable possibility” means there is evidence to suggest a causal relationship between the drug and the adverse event.  “Suspected adverse reaction” implies a lesser degree of certainty about causality than adverse reaction, which means any adverse event caused by a drug.  
 
C. Life-Threatening Adverse Event / Life Threatening Suspected Adverse Reaction  
 
As defined in 21 CFR 312.32:  
 Definition:  any adverse drug event or suspected adverse reaction is considered “life -
threatening” if, in the view of the investigator , its occurrence places the patient  at 
immediate risk of death . It does not include an adverse event or suspected adverse reaction  
that, had it occurred in a more severe form, might have caused death. 
 
D. Serious Adverse Event (SAE)  or Serious Suspected Adverse Reaction  
 
As defined in 21 CFR 312.32:  
 Definition:  an adverse event or suspected adverse reaction is considered “serious” if, in 
the view of the investigator, it results in any of the following outcomes:  
o Death  
Protocol Version:  05/16/2022 – Amendment 7  Page 78 of 83 o A life -threatening adverse event  
o Inpatient hospi[INVESTIGATOR_1081] . The  following 
hospi[INVESTIGATOR_102412]:  
• a visit to the emergency room or other hospi[INVESTIGATOR_20347] < 24 hours, that 
does not result in admission (unless considered an important medical or life -
threatening event)  
• electiv e surgery, planned prior to signing consent  
• admissions as per protocol for a planned medical/surgical procedure  
• routine health assessment requiring admission for baseline/trending of 
health status (e.g., routine colonoscopy)  
• medical/surgical admission othe r than to remedy ill health and planned prior 
to entry into the study. Appropriate documentation is required in these cases  
• admission encountered for another life circumstance that carries no bearing 
on health status and requires no medical/surgical interv ention (e.g., lack of 
housing, economic inadequacy, caregiver respi[INVESTIGATOR_040], family circumstances, 
administrative reason)  
• admission for administration of anticancer therapy in the absence of any other SAEs (applies to oncology protocols)  
o A persistent or signific ant incapacity or  substantial disruption of a person’s ability 
to conduct normal life functions  
o A congenital anomaly/birth defect  
o Any other important medical event that does not fit the criteria above but,  based 
upon appropriate medical judgment, may jeopa rdize the subject and may require 
medical or surgical intervention to prevent one of the outcomes listed above  
 
E. Protocol Exceptions  
 
Definition:  A planned change in the conduct of the research for one participant . 
 
F. Deviation  
 Definition:  Any alteration or modification to the IRB -approved research without 
prospective IRB approval.  The term “research” encompasses all IRB -approved materials 
and documents including the detailed protocol, IRB application, consent form, recruitment materials, questionnaires/data collection forms, and any other information relating to the 
research study.  
 
A minor or administrative deviation is one that does not have the potential to negatively 
impact the rights, safety, or welfare of participants or others or the scientific validity of the 
study.  
 A major deviation is one that does have the potential to negatively impact the rights, safety, 
or welfare of participants or others or the scientific validity of the study.  
  
 
 
Protocol Version:  05/16/2022 – Amendment 7  Page 79 of 83 APPENDIX G: Reporting Timelines  
Expedited Reporting Timelines  
Event  HRPO  QASMC  FDA  Bristol Myers -Squibb  
Serious AND 
unexpected suspected 
adverse reaction    Report no later than 15 calendar 
days after it is determined that the 
information qualifies for reporting  Report to BMS within 24 hours \ 
1 Business Day of becoming 
aware of the event  
Unexpected fatal or 
life-threatening 
suspected adverse 
reaction    Report no later than 7 calendar days 
after initial receipt of the 
information  Report to BMS within 24 hours \ 
1 Business Day of becoming 
aware of the event  
Unanticipated 
problem involving risk 
to participants or 
others  Report within 10 working days.  
If the event results in the death 
of a participant enrolled at 
WU/BJH/SLCH, report within 
1 working day.  Report via email after IRB 
acknowledgment    
Major deviation  Report within 10 working days.  
If the event results in the death 
of a participant enrolled at 
WU/BJH/SLCH, report within 
[ADDRESS_1181071] in the protocol 
or IB    Report no later than 15 calendar 
days after it is determined that the 
information qualifies for reporting   
Complaints  If the complaint reveals an 
unanticipated problem    
Protocol Version:  05/16/2022 – Amendment 7  Page 80 of 83 Expedited Reporting Timelines  
Event  HRPO  QASMC  FDA  Bristol Myers -Squibb  
involving risks to participants 
or others OR noncompliance, 
report within 10 working days.  
If the even t results in the death 
of a participant enrolled at 
WU/BJH/SLCH, report within 
1 working day.  Otherwise, 
report at the time of continuing 
review.  
Breach of 
confidentiality  Within 10 working days.     
Incarceration  If withdrawing the participant 
poses a safety issue, report 
within 10 working days.   
 
If withdrawing the participant does not represent a safety issue 
and the patient will be 
withdrawn, report at continuing 
review.     
Pregnancy     Report to BMS within 24  hours \ 
1 Business Day of becoming 
aware of the event  
 
         
Protocol Version:  05/16/2022 – Amendment [ADDRESS_1181072] current 
toxicity table fr om the 
DSM report is provided to the FDA with the 
IND’s annual report.   
Minor deviation  Report summary information at the time of 
continuing review.     
Complaints  If the complaint reveals an unanticipated problem 
involving risks to participants or others  OR 
noncompliance, report within 10 working days.  If the event results in the death of a participant 
enrolled at WU/BJH/SLCH, report within 1 
working day.  Otherwise, report at the time of 
continuing review.     
Incarceration  If withdrawing the participan t poses a safety 
issue, report within 10 working days.   
 
If withdrawing the participant does not represent a 
safety issue and the patient will be withdrawn, 
report at continuing review.     
Pregnancy     Report to BMS within 24 hours 
\ 1 Business Day of becoming 
aware of the event  
 
 
 
   
Protocol Version:  05/16/2022 – Amendment 7  Page 82 of 83 Expedited Reporting Timelines for Secondary Sites  
Event  WU (Coordinating Center)  Local IRB  FDA  Bristol Myers -Squibb  
Serious AND unexpected 
suspected adverse reaction  Report no later than [ADDRESS_1181073] be obtained prior to 
implementing the change.  
 
                 
Protocol Version:  05/16/2022 – Amendment 7  Page 83 of 83 APPENDIX H:  Washington University Serious Adverse Event Reporting Cover 
Sheet  
 
SAE COVER SHEET - Secondary Site Assessment  
 
Washington University  HRPO#:  Sponsor -Investigator:  
Subject Initials:   Subject ID:  
Treating MD:  Treating Site:  
EVENT TERM:  Event Start  Date:  
EVENT GRADE:  Date of site’s first notification:  
 
Treating MD Event Assessment:  
 
 
Is this event possibly, probably, or definitely related study treatment?  
 
 Yes    No 
 If yes, please list wh ich drug (if more than one) ______________________________ 
 
       Explain  ______________________________________________________________________ 
 
______________________________________________________________________________ 
 
  _________________________           ___________________________      _________________  
Physician’s Name    [CONTACT_17827]’s Signature   [CONTACT_1782]  